News
Entertainment
Science & Technology
Life
Culture & Art
Hobbies
News
Entertainment
Science & Technology
Culture & Art
Hobbies
Iron Ore Falls to 1-Week Low on Rising Supply - ForexTV
Iron ore futures fell to approximately CNY 700 per tonne on Thursday, reaching a one-week low as the supply from leading exporters increased. Shipments to China by top producers Australia and Brazil reached 30.1 million tonnes last week, marking the highest weekly total of the year thus far, based on industry statistics. Brazilian mining company Vale increased its exports in a final push before the season ends, while Australia's Rio Tinto obtained final government approval for its Hope Downs 2 project, a collaboration with Hancock Prospecting. This new mine is anticipated to generate 31 million tonnes per year, which will further augment global supply. On the demand side, the World Steel Association reported that global steel production decreased by 3.8% year-on-year in May, highlighting ongoing weaknesses in the construction and manufacturing sectors.The material has been provided by InstaForex Company - www.instaforex.com
The new version of the Articles of Association of UAB Urbo bankas was registered - ForexTV
Urbo bankas UAB (hereinafter - “the Bank”), company code 112027077, address: Konstitucijos pr.18B, Vilnius. We hereby inform you that on 25 June 2025, a new version of the Articles of Association of the Bank was registered in the Register of Legal Entities. The Articles of Association was approved on 21 March 2025 during the Ordinary General Meeting of Shareholders of the Bank. For more information please contact: Julius Ivaška, Head of Business Division, tel. +370 601 04 453, e-mail media@urbo.lt Attachment Urbo bankas Article of Association
Hungary's Current Account Surges to 1.140 Billion Euros in Q1 2025 - ForexTV
In a remarkable turn of events, Hungary's current account has climbed to an impressive 1.140 billion euros in the first quarter of 2025, showcasing significant economic momentum from the previous quarter. This figure marks a substantial leap from the 0.080 billion euros recorded in the fourth quarter of 2024, reflecting a robust quarter-over-quarter growth that surpasses the previous quarter's modest gains.The dramatic improvement in Hungary's current account suggests a period of strengthened economic activity and a potential uptick in the country's international transactions and trade balance. Such a sizable increase in the current account balance could indicate a surge in exports, a reduction in imports, or an influx of foreign investment, all of which are pivotal elements of a country's economic health.Updated on June 26, 2025, these data points underscore Hungary's dynamic economic trajectory and the possible implications for policy makers and investors looking at the European financial landscape. As the country navigates through global economic shifts, this surge in its current account is a testament to Hungary's strategic economic positioning in the face of fluctuating international markets.The material has been provided by InstaForex Company - www.instaforex.com
Silver Holds Gains Amid Weaker Dollar, Treasury Yields - ForexTV
Silver prices maintained their strength above $36.20 per ounce on Thursday, following an almost 1% increase in the previous session. This stability is attributed to the combination of a weaker dollar and declining Treasury yields, which continue to bolster the metal's value. The current market dynamics arise amid heightened anticipation of Federal Reserve rate cuts, influenced by dovish indicators from Chair Jerome Powell. On Wednesday, Powell emphasized that interest rates should stay unchanged due to inflation risks associated with the Trump administration's tariffs, while also suggesting that without these tariffs, the Fed might have continued easing measures. In the geopolitical arena, US officials are set to engage in talks with Iranian representatives next week, and the ceasefire between Iran and Israel remains in effect. Complementing these broader economic factors, silver has gained from robust industrial demand and ongoing supply limitations. Notably, silver has significantly outshone gold in June, recording an approximate 10% increase, compared to gold's modest rise of just over 1%.The material has been provided by InstaForex Company - www.instaforex.com
Hungary Current Account Surplus Widens Sharply - ForexTV
Hungary's current account surplus significantly decreased to €1.14 billion in the first quarter of 2025, compared to €2.21 billion in the same period the previous year. This reduction is primarily attributed to a decline in the services account surplus, which fell to €1.95 billion from €2.1 billion the year before. In addition, the goods account surplus slightly decreased to €1.12 billion from €1.13 billion. Furthermore, the primary income deficit widened to €1.52 billion from €0.92 billion, and the secondary income shortfall increased to €0.41 billion from €0.1 billion during the same timeframe last year.The material has been provided by InstaForex Company - www.instaforex.com
Garrett Inaugurates Wuhan Innovation Center to Advance Zero-Emission Mobility - ForexTV
Garrett opens second innovation center in China to expand zero-emission R&D capabilitiesNew Wuhan lab prioritizes high-speed E-Powertrain systems for zero-emission applications Wuhan and Shanghai now form dual innovation hubs driving global collaboration WUHAN, China, June 26, 2025 (GLOBE NEWSWIRE) -- Garrett Motion Inc. (NASDAQ: GTX), a global leader in differentiated automotive technologies, today inaugurated its new Wuhan Innovation Center. Located within Garrett’s Wuhan Plant, the facility strengthens the company’s global and China-based zero-emission R&D footprint. As Garrett’s second innovation hub in China, it joins the Shanghai R&D Center to form a powerful “dual innovation engine” advancing motion in every form - from turbocharging leadership to zero-emission differentiated solutions across mobility and beyond. “The launch of our Wuhan Innovation Center marks a bold step forward in Garrett’s electrification journey," said Olivier Rabiller, President and CEO of Garrett Motion. "We are scaling our zero-emission capabilities where innovation is happening fastest—right here in China. This new hub strengthens our global technology engine and reinforces Garrett’s position as a differentiated technology provider in decarbonizing mobility and industry alike.” Mr. Li Feng, Chief Inspector of Wuhan East Lake High-tech Development Zone, attended the event and commented: “Automotive is one of Wuhan’s most dynamic industries, and we are pleased to see a global leader like Garrett deepen its presence here. The new Innovation Center marks an important step in Wuhan’s ongoing efforts to promote high-level openness and industrial development, and it strengthens our role as a national hub for science and technology.” 20 Years of Innovation in China: Accelerating Local R&D Expansion For 70 years, Garrett has advanced mobility technologies around the world, developing numerous industry-first technologies—from variable geometry turbines to air-bearing compressors for hydrogen fuel cells. In China, Garrett has built two decades of innovation since establishing its Shanghai R&D Center in 2005. The company has developed and industrialized a range of China-specific solutions such as: Gasoline Variable Nozzle Turbine (VNT) turbos to boost thermal efficiency, improving fuel efficiency.Wastegate turbochargers optimized for PHEVs (Plug-in Hybrid Electric Vehicles) and REEVs (Range-Extended Electric Vehicles) increasing range while optimizing CO2 emissions. Hydrogen fuel cell compressors serving both LV (Light Vehicle) and CV (Commercial Vehicle) customers. These innovations not only support Chinese OEMs locally but also help them expand business globally. With the launch of the Wuhan Innovation Center, Garrett enters a new phase—reinforcing long-term investment in China and expanding its innovation footprint in zero-emission mobility and beyond. Driving Zero-Emission Innovation Across Mobility and Beyond As electrification accelerates across the automotive sector, Garrett is scaling its portfolio of zero-emission technologies. Leveraging core strengths in high-speed motors, power electronics, controls software, oil-less bearings, and system integration, Garrett is advancing solutions including: 3-in-1 E-Powertrain systems;E-Cooling refrigerant compressors;Established fuel cell compressors. The company’s high-speed, high-power density E-Powertrain integrates an electric motor, inverter, and gearbox—reducing system size and weight by up to 40%. Featuring speeds up to 35,000 rpm and high-efficiency inverters, the system cuts use of critical materials by ~30%. It supports 400V and 800V vehicle architectures. First unveiled at the 2025 Shanghai Auto Show, the E-Powertrain has already secured its first series production order with HanDe for heavy-duty trucks—marking a key commercial milestone. The Wuhan Innovation Center is focused on accelerating development of these zero-emission systems. Inverter testing is already operational, with further expansions planned to cover full power electronics validation—including compressors for fuel cells and e-cooling systems—supporting both automotive and industrial decarbonization. A Strategic Hub for Innovation and Collaboration "The Wuhan Innovation Center is a clear embodiment of Garrett's 'East for East' strategy," said Jessica Zhang, Vice President and General Manager, Garrett China. "By integrating R&D and manufacturing capabilities in China, we are accelerating the commercialization of zero-emission technologies—from prototype through testing to production." The new Center also serves as a collaboration platform—attracting cross-disciplinary talent and forging partnerships with academic institutions, research bodies, and industry players to fuel the next wave of innovation. About Garrett Motion Inc. A differentiated technology leader, Garrett Motion has a 70-year history of innovation in the automotive sector (cars, trucks) and beyond (off-highway equipment, marine, power generators). Its expertise in turbocharging has enabled significant reductions in engine size, fuel consumption, and CO2 emissions. Garrett is expanding its positive impact by developing differentiated technology solutions for Zero Emission Vehicles, such as fuel cell compressors for hydrogen fuel cell vehicles, as well as electric propulsion and thermal management systems for battery electric vehicles. Garrett has now six R&D centers, 13 manufacturing facilities and a team of more than 9,000 employees in more than 20 countries. Its mission is to enable the transportation industry to advance motion through unique, differentiated innovation. For more information, please visit www.garrettmotion.com. About Garrett Motion China Garrett established its presence in China in 1994 and was among the first global companies to introduce turbocharging technology into the country. Headquartered in Shanghai, Garrett has two world-class, advanced manufacturing facilities in Shanghai and Wuhan, as well as 2 innovation centers. The company employs more than 1,000 people, including a China R&D team of over 200 specialists with end-to-end engineering and service capabilities. Garrett boasts lasting partnerships with more than 30 global and Chinese automakers. It offers a comprehensive portfolio of turbocharging technology for gasoline, diesel, natural gas, hybrid and zero emission technology for battery electric vehicles in automotive sector and beyond. CONTACTS: Global MediaInvestor RelationsAmanda JonesCyril Grandjeanamanda.jones@garrettmotion.cominvestorrelations@garrettmotion.com Cell. +41 79 601 07 87Cell. +1 734 392 5504 CHINA MediaYang Huyang.hu1@garrettmotion.com Cell. +86 189 1760 6610 A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/6c4e0510-f3ac-4f3a-bbdb-000ee34f97ee
Share Buybacks, Acquisitions, Arms Industry: Strategic Pillars to 2027 - ForexTV
The share buyback programme for employees was approved at the Annual General Meeting held on December 10, 2024. Following approval, several months were required to prepare for the programme’s launch, due to the need to comply with a complex legislative and regulatory framework that ensures transparency and adherence to both internal and external rules. GEVORKYAN, a.s. announces the implementation of its share buyback programme for the period from June 24, 2025 to June 10, 2026. The sole purpose of this buyback is to distribute the company’s shares to to employees under the Employee Stock Ownership Plan (ESOP) in accordance with Article 5(2)(c) of the Market Abuse Regulation (MAR). The programme is also planned for key employees involved in ongoing acquisitions. GEVORKYAN, a.s. continues to strengthen its market position by diversifying its customer portfolio and acquiring projects with a focus on the arms industry. Media contact: Monika Erdely, Marketing Manager, marketing@gevorkyan.sk Attention: This document in no way constitutes an offer or invitation to sell or buy securities. The information contained in this document is for informational purposes only and we recommend that you contact the above-mentioned representative of GEVORKYAN, a.s. for context and clarification. The public offering of shares in the Czech Republic was made on the basis of a prospectus for the shares prepared pursuant to Regulation (EU) 2017/1129 of the European Parliament and of the Council on prospectuses, which is available on the website of GEVORKYAN, a.s. Vlkanová, Slovakia 26 June 2025
FPC welcomes two new board members to accelerate strategic growth - ForexTV
Gothenburg, Sweden – June 26, 2025 – Fingerprint Cards AB (FPC) is pleased to announce the appointment of two distinguished new members to its Board of Directors following the company’s Annual General Meeting held on 24th June, 2025. The shareholders voted in favour of appointing John Lord and Carl Johan Grandinson to the board, marking a pivotal step in FPC’s evolution as it enters an exciting new chapter of innovation and strategic transformation. Introducing Our New Board MembersJohn Lord brings over 25 years of leadership experience across global financial and technology enterprises. Beginning his career at Euler Hermes (1990–1995) and RBS Commercial Finance (1996–1998), he progressed to C-level leadership roles in GE Finance and Dun & Bradstreet UK & Ireland (2000–2007). Lord later served as Group Sales & Marketing Director at LBM Direct Marketing and then as Group Managing Director of GBG plc (2009–2016). In 2016, he founded and led TruNarrative as CEO until 2021, and currently holds chair and investor roles at Panintelligence, Relative Insight, and Engage PSG Search. His background in finance, risk, and SaaS—especially in identity verification—provides FPC with valuable strategic oversight in growing enterprise-facing biometric solutions. Carl Johan Grandinson offers deep expertise at the intersection of technology, marketing, and operational scaling. With an MSc in Mechanical Engineering (KTH) and media/marketing studies at Stockholm School of Economics and Stanford, he began as TradeDoubler’s first employee (1999–2007), rising to Regional Director overseeing Nordic and Southern Europe. He then co-founded the award-winning Media Agency Tre Kronor Media (2007-2015) and later co-founded Glue Home (2015-2021), a smart-lock and InHome delivery platform company. Currently, he is working with growth equity investments in enterprise software companies as Founding Partner at Qvantea Capital (2021-). Strategic Significance of Their AppointmentJohn and Carl Johan join FPC at a transformational time for the company. As FPC expands its solutions up the value chain, across embedded biometrics and secure access technologies, these new board members offer complementary strengths that will reinforce the company’s strategic capabilities. John Lord’s global market insight and innovation leadership will bolster FPC’s go-to-market initiatives, especially in new verticals where advanced biometric authentication is in high demand. His experience guiding businesses through technological shifts aligns seamlessly with FPC’s vision for smarter, more secure biometric solutions. Carl Johan Grandinson’s financial and strategic acumen will add critical depth to FPC’s governance and capital planning, supporting the company’s drive toward long-term sustainability and profitability. His track record of working across transformative technology landscapes makes him particularly well-suited to help guide FPC’s operational and strategic roadmap. Christian Lagerling, Chairman at FPC, commented:“We are thrilled to welcome John and Carl Johan to our board. Their combined experience, leadership, and deep industry knowledge will be invaluable as we pursue our new strategic direction. This is a pivotal time for FPC, and their appointments reinforce our commitment to bold innovation, operational excellence, and long-term value creation for our shareholders and customers.” For more information about FPC please visit www.fpc.com. For further information, please contact:Adam Philpott, CEO Investor Relations: +46(0)10-172 00 10, investrel@fpc.com Press: +46(0)10-172 00 20, press@fpc.com About FPCFingerprint Cards AB (FPC) is a global biometrics leader, offering intelligent edge to cloud biometrics. We envision a secure, seamless world where you are the key to everything. Our solutions – trusted by enterprises, fintechs, and OEMs – power hundreds of millions of products, enabling billions of secure, convenient authentications daily across devices, cards, and digital platforms. From consumer electronics to cybersecurity and enterprise, our cloud-based identity management platforms support multiple biometric modalities, including fingerprints, iris, facial, and more. With improved security and user experience, we are driving the world to passwordless. Discover more at our website and follow us on LinkedIn and X for the latest updates. FPC is listed on Nasdaq Stockholm (FING B). Attachment 250626 - New Board Members
DEMIRE increases ESG performance: Company's own CO₂ emissions reduced by 40 percent, smart meter initiative expanded - ForexTV
DEMIRE increases ESG performance: Company's own CO₂ emissions reduced by 40 percent, smart meter initiative expanded Langen, 26 June 2025. DEMIRE Deutsche Mittelstand Real Estate AG (“DEMIRE”; ISIN: DE000A0XFSF0) made decisive progress in climate protection and sustainable corporate governance in 2024: CO₂ emissions were reduced by 40 percent, ESG data collection was extended to over three quarters of the portfolio and the first green leases were implemented. Strategic development is also part of the sustainability report published today, which comprehensively documents current progress. “We are investing in transparency and controllability - both are crucial to achieving our decarbonization goals strategically and economically,” explains Frank Nickel, CEO of DEMIRE. “In doing so, we combine operational action with strategic foresight - for us, this is the key to successful transformation.” Targeted expansion of the ESG database The integration of 14 additional properties has expanded ESG data collection to 76 percent of the portfolio. This improved database enables even more precise management of sustainability measures. CO₂ reduction & green electricity conversion Initial technical optimizations, for example in Rostock, have already led to noticeable savings. The conversion of general electricity to green electricity is well advanced and should be completed by Q3 2025. Strategic development despite regulatory changes Although DEMIRE is temporarily no longer subject to CSRD reporting requirements, a comprehensive materiality analysis was carried out in 2024. CFO Tim Brückner emphasizes: “Despite regulatory relief, we continue to focus on high ESG standards - because climate protection in the portfolio is not only possible but also makes economic sense.” Company's own CO₂ emissions significantly reduced Since 2022, DEMIRE has reduced its own CO₂ emissions by 40 percent by switching to green energy in the office and low-emission mobility. In 2024, the remaining emissions were 58.9 tons of CO₂ - these were fully offset. Outlook: Green leases & charging infrastructure In 2025 DEMIRE intends to further advance the digitalization of its portfolio: smart meters are to be rolled out more widely and green leases increasingly implemented to transparently record tenant consumption. At the same time, the charging infrastructure for e-mobility will be expanded and further properties will be technically optimized. The current sustainability report was prepared in accordance with the EPRA Sustainability Best Practices Recommendations (sBPR) and externally audited. -End of press release- You can find the full sustainability report here: https://www.demire.ag/en/publications/ About DEMIRE Deutsche Mittelstand Real Estate AG DEMIRE Deutsche Mittelstand Real Estate AG acquires and holds commercial properties in medium-sized cities and up-and-coming peripheral locations in metropolitan areas throughout Germany. The company's particular strength lies in realising real estate potential in these locations and focuses on an offering that is attractive to both international and regional tenants. As of 31 March 2025, DEMIRE had a real estate portfolio of 49 properties with a lettable area of around 594 thousand square metres. Taking into account the proportionately acquired Cielo property in Frankfurt/Main, the market value amounts to around EUR 1.0 billion. The portfolio's focus on office properties with an admixture of retail and hotel properties is appropriate for the risk/return structure of the commercial property segment. The Company attaches great importance to long-term contracts with solvent tenants and the realisation of potential and therefore continues to expect stable and sustainable rental income and solid value growth. DEMIRE's portfolio is to be significantly expanded in the medium term. In expanding the portfolio, DEMIRE will focus on FFO-strong assets with potential, while properties that do not conform to the strategy will continue to be sold in a targeted manner. DEMIRE will continue to develop its operations and processes with numerous measures. In addition to cost discipline, operating performance is being improved through an active asset and portfolio management approach.The shares of DEMIRE Deutsche Mittelstand Real Estate AG (ISIN: DE000A0XFSF0) are listed in the Prime Standard of the German Stock Exchange in Frankfurt. Contact: Julius StinauerHead of Investor Relations & Corporate FinanceT: +49 6103 372 49 44E: ir@demire.ag
German Consumer Morale Below Estimates - ForexTV
Germany's GfK Consumer Climate Indicator slightly declined to -20.3 as we approached July 2025, down from a slightly revised -20.0 in June. This marks the first decline over the past four months and fell short of market expectations, which predicted a -19.3 reading. The inclination to save reached a 13-month peak, moving to 13.9 from 10.0, while the willingness to make purchases remained low at -6.2 compared to -6.4 previously. However, economic outlook improved, rising to 20.1 from 13.1—the highest level since the onset of the Ukraine conflict in February 2022—propelled by forthcoming government investments in defense and infrastructure. For the fourth consecutive month, income expectations rose to 12.8 from 10.4, aided by favorable wage negotiations and decreasing inflation. According to Rolf Bürkl, a consumer specialist at NIM, "A strong propensity to save reflects ongoing uncertainty and a lack of stability in planning," which adversely impacts significant purchases. The report also highlights apprehension due to uncertainty surrounding U.S. trade policies.The material has been provided by InstaForex Company - www.instaforex.com
Silver Rises as Dollar and Yields Retreat - ForexTV
Silver prices advanced toward $36 per ounce on Wednesday, rebounding from over two-week lows. This rise was bolstered by a weakening US dollar and declining Treasury yields. The increase occurred as geopolitical tensions showed signs of easing, with the US-brokered ceasefire between Israel and Iran holding steady despite occasional minor skirmishes. However, intelligence reports suggested that recent US missile strikes have only partially impaired Iran's nuclear capabilities, delaying but not dismantling its program. Meanwhile, Federal Reserve Chair Jerome Powell highlighted a flexible stance on monetary policy, suggesting that “many paths are possible" and leaving room for a possible rate cut in July. He underscored a cautious approach, indicating that the Fed would respond promptly should signs of labor market weakness arise. Furthermore, silver's value continued to be buoyed by robust industrial demand and persistent supply limitations. The metal has outperformed gold this month, appreciating roughly 9% in June, compared to gold's increase of just over 1%.The material has been provided by InstaForex Company - www.instaforex.com
LIfT BioSciences Expands U.S. Footprint with New Facility at Portal Innovations, Houston Helix Park - ForexTV
LIfT BioSciences Expands U.S. Footprint with New Facility at Portal Innovations, Houston Helix Park London, 25 June 2025– LIfT BioSciences, (‘LIfT’ or ‘the Company’), a rapidly emerging biotech and the global leader in neutrophil immunotherapies, today announces it has entered into an agreement with Portal Innovations, a life sciences venture capital firm, providing LIfT with access to Portal’s state-of-the-art 30,000 sq. ft. labs and office space in Houston Helix Park, Texas, one of the fastest growing life-science ecosystems in the United States. This strategic expansion significantly strengthens LIfT’s transatlantic footprint, complementing its existing operations in the United Kingdom, Ireland, and United States, and positioning the Company to accelerate the development of its first-in-class Immuno-Modulatory Alpha Neutrophils (IMANs) designed to overcome treatment resistance in solid tumours. Alex Blyth, Chief Executive Officer of LIfT Biosciences said: “In addition to premium lab and office spaces, Portal Innovations provides LIfT with a unique ecosystem of scientific expertise, with proximity to the highly distinguished clinical trial center in MD Anderson. It is an important milestone in our journey to deliver curative neutrophil immunotherapies to patients globally.” Zach Hightower, Director of Business Development at Portal Innovations added: “Portal Innovations is designed to help innovative companies like LIfT move rapidly from discovery to clinical and commercial success through curated capital, best-in-class infrastructure, and access to a strong life sciences network. LIfT’s novel immunotherapy approach exemplifies the innovative science that we aim to support, and we believe they will be a great fit in our collaborative environment. We look forward to welcoming them into our growing Houston ecosystem.” As part of this agreement, LIfT will benefit from Portal’s fully serviced laboratory environment, tailored operational and safety support, and a robust programme of networking, investor events, and expert advisory resources, allowing LIfT to scale its U.S. operations as it advances its clinical programs. Houston Helix Park’s ecosystem includes academic and clinical leaders; all of whom offer potential collaboration opportunities as LIfT advances its platform toward clinical translation. Portal’s venture development model also offers access to strategic capital, providing LIfT with flexible options to support future U.S. growth. About LIfT BioSciencesLIfT Biosciences is a UK & Ireland biotech that is bringing to market a first-in-class allogeneic alpha neutrophil immunotherapy that overcomes treatment resistance in solid tumours by reconstituting immune competence. LIfT’s Immunomodulatory Alpha Neutrophils (IMANs) kill in a non-antigen specific manner and turn the tumour microenvironment against the tumour to give a durable total immune response and lasting immunity. The patented breakthrough N-LIfT platform is produced using exceptional stem cells (iPSC or HSC), a proprietary enhancement media and genetic engineering. The company is preparing initiatives with a range of pharmaceutical license partners to develop a portfolio of engineered IMAN immunotherapies to destroy a range of solid tumours. See www.LIfTBiosciences.com. Further informationInvestors:Alex Blyth ablyth@LIfTBioSciences.com Media:ICR Healthcare Lindsey Neville, Namrata Taak, Evi Useh liftbiosciences@icrhealthcare.com
WISeSat Signs a Service Agreement with Astrocast to Allow Access to Astrocast’s Operational Satellite Constellation - ForexTV
FOR IMMEDIATE RELEASE WISeSat Signs a Service Agreement with Astrocast to Allow Access to Astrocast’s Operational Satellite Constellation Geneva, Switzerland – June 25, 2025 – WISeKey International Holding Ltd (“WISeKey”) (SIX: WIHN, NASDAQ: WKEY), a leading global cybersecurity, blockchain, and IoT company, today announces that its subsidiary, WISeSat.Space, a provider of secure satellite communications and space infrastructure, signed a strategic collaboration agreement with Astrocast, a Swiss-based nanosatellite IoT network operator, under which WISeSat will be gaining access to the operational satellite constellation of Astrocast. This collaboration significantly expands WISeSat’s existing operational satellite connectivity as Astrocast operates one of the largest LEO satellite networks in Europe. This agreement marks a major step in WISeSat’s mission to build a fully sovereign and secure European space ecosystem, aligned with EU space autonomy goals and ambitions. The expanded constellation access will strengthen connectivity, resilience, and coverage for Internet of Things (IoT) and critical infrastructure services across Europe and other strategic global regions. Carlos Moreira, CEO of WISeKey and WISeSat.Space, stated: “This is a decisive moment for the future of secure space communications in Europe. By utilizing Astrocast’s operational constellation, WISeSat’s is not only expanding its orbital reach, but it is also reinforcing Europe’s strategic autonomy in space. This partnership allows us to deliver more robust, real-time, and cyber-secure satellite-based services across key industries and geographies. It’s a powerful example of how Swiss-led innovation can shape the future of a sovereign, digital Europe.” This service agreement with Astrocast will support WISeSat’s secure IoT and communication services, which are powered by WISeKey’s cybersecurity and digital identity technologies, and deployed across sectors such as agriculture, environmental monitoring, logistics, energy, and defense. Fabien Jordan, CEO of Astrocast, added: “After a very challenging period of restructuring, the Astrocast constellation remains very reliable. We are excited to make this unique network usable for WISeSat and to help them shape the future of secure European space related services. This partnership demonstrates the power of collaboration in advancing innovation and delivering high-value, satellite IoT solutions.” This agreement also paves the way for deeper cooperation in areas such as edge AI in space, post-quantum cryptography, and satellite cybersecurity, further cementing Europe’s leadership in next-generation space technology. About Astrocast Astrocast SA operates a global nanosatellite IoT network, enabling reliable and cost-effective connectivity for remote and underserved regions. With a strong focus on innovation, Astrocast’s technology supports a wide range of industrial and environmental applications. About WISeSat.Space WISeSat.Space, a subsidiary of WISeKey International Holding Ltd (SIX: WIHN, NASDAQ: WKEY), provides secure satellite infrastructure designed to support sovereign European communications, IoT services, and critical mission applications. Its constellation of small satellites ensures end-to-end security and data sovereignty across strategic sectors. About WISeKey WISeKey International Holding Ltd (“WISeKey”, SIX: WIHN; Nasdaq: WKEY) is a global leader in cybersecurity, digital identity, and IoT solutions platform. It operates as a Swiss-based holding company through several operational subsidiaries, each dedicated to specific aspects of its technology portfolio. The subsidiaries include (i) SEALSQ Corp (Nasdaq: LAES), which focuses on semiconductors, PKI, and post-quantum technology products, (ii) WISeKey SA which specializes in RoT and PKI solutions for secure authentication and identification in IoT, Blockchain, and AI, (iii) WISeSat AG which focuses on space technology for secure satellite communication, specifically for IoT applications, (iv) WISe.ART Corp which focuses on trusted blockchain NFTs and operates the WISe.ART marketplace for secure NFT transactions, and (v) SEALCOIN AG which focuses on decentralized physical internet with DePIN technology and house the development of the SEALCOIN platform.Each subsidiary contributes to WISeKey’s mission of securing the internet while focusing on their respective areas of research and expertise. Their technologies seamlessly integrate into the comprehensive WISeKey platform. WISeKey secures digital identity ecosystems for individuals and objects using Blockchain, AI, and IoT technologies. With over 1.6 billion microchips deployed across various IoT sectors, WISeKey plays a vital role in securing the Internet of Everything. The company’s semiconductors generate valuable Big Data that, when analyzed with AI, enable predictive equipment failure prevention. Trusted by the OISTE/WISeKey cryptographic Root of Trust, WISeKey provides secure authentication and identification for IoT, Blockchain, and AI applications. The WISeKey Root of Trust ensures the integrity of online transactions between objects and people. For more information on WISeKey’s strategic direction and its subsidiary companies, please visit www.wisekey.com. DisclaimerThis communication expressly or implicitly contains certain forward-looking statements concerning WISeKey International Holding Ltd and its business. Such statements involve certain known and unknown risks, uncertainties and other factors, which could cause the actual results, financial condition, performance or achievements of WISeKey International Holding Ltd to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. WISeKey International Holding Ltd is providing this communication as of this date and does not undertake to update any forward-looking statements contained herein as a result of new information, future events or otherwise. This press release does not constitute an offer to sell, or a solicitation of an offer to buy, any securities, and it does not constitute an offering prospectus within the meaning of the Swiss Financial Services Act (“FinSA”), the FinSa's predecessor legislation or advertising within the meaning of the FinSA. Investors must rely on their own evaluation of WISeKey and its securities, including the merits and risks involved. Nothing contained herein is, or shall be relied on as, a promise or representation as to the future performance of WISeKey.Press and Investor Contacts WISeKey International Holding LtdCompany Contact: Carlos MoreiraChairman & CEOTel: +41 22 594 3000info@wisekey.com Media ContactsWISeSat.Space – press@wisesat.spaceWISeKey Investor Relations (US) The Equity Group Inc.Lena CatiTel: +1 212 836-9611 lcati@theequitygroup.com
Spanish GDP Growth Slows to 0.6% in Q1 2025 - ForexTV
Spain's economic momentum slightly cooled in the first quarter of 2025, with the GDP growth rate slowing to 0.6% from the previous quarter's 0.7%, according to the latest data updated on June 25, 2025. This marginal decrease reflects a moderate dip in the pace of economic expansion as compared to the last quarter of 2024.The quarter-over-quarter comparison highlights a sluggish start to the new year for Spain's economy. While the GDP managed to maintain positive growth, the decline from 0.7% to 0.6% suggests potential headwinds that might be affecting sectors within the economy. Analysts are keeping a close eye on factors such as inflation, consumer spending, and external trade dynamics that could be influencing this downward adjustment in growth.As Spain navigates through 2025, economic stakeholders will be evaluating whether this slowdown is a temporary blip or indicative of broader economic challenges. Future quarterly data releases will be crucial in assessing the underlying health of the Spanish economy and in shaping fiscal and monetary policy responses accordingly.The material has been provided by InstaForex Company - www.instaforex.com
Repeat: Norsk Hydro: Hydro's second quarter results 2025 - ForexTV
Norsk Hydro: Hydro's second quarter results 2025 Hydro's second quarter results 2025 will be released at 07:00 CEST (01:00 EDT, 06:00 BST, 05:00 UTC/GMT) on July 22, 2025. The quarterly report and presentation will be available on hydro.com at the same time as the release. President and CEO Eivind Kallevik and Executive Vice President and CFO Trond Olaf Christophersen, will host a webinar in English at 08:30 CEST the same day. There will be a Q&A session directly after the presentation. There will be no physical presentation or press conference. To join the webinar and ask questions, use the link to our webcast page. The webcast is powered by Zoom. No login or registration in advance is required. It is also possible to log in using the dial-in option: Norway +47 2400 4736 London, UK +44 330 088 5830 New York, US +1 929 205 6099 Find your local number Meeting ID: 916 4818 8026 We advise you to investigate in advance if your company has any restrictions using the Zoom platform. Investor contact: Martine Rambøl Hagen +47 91708918 martine.rambol.hagen@hydro.com
Norway Loan Debt Growth Steady at 4.1% in May - ForexTV
As of the end of May 2025, Norway's public domestic loan debt experienced a year-on-year increase of 4.1%, reaching NOK 7.64 billion. This growth rate matched that of the previous month and marks the most significant rise in domestic loan debt since September 2023. A notable factor in this increase was the loan debt of municipal governments, which climbed to 7.6% from 7.4% in April. Meanwhile, the debt levels for households held steady at 4.2%, and for non-financial corporations at 2.7%.The material has been provided by InstaForex Company - www.instaforex.com
Idorsia launches repurchase offer for its 2025 and 2028 convertible bonds - ForexTV
Ad hoc announcement pursuant to Art. 53 LR Allschwil, Switzerland – June 25, 2025Idorsia Ltd (SIX: IDIA) today announced the launch of the repurchase offer to the holders of its outstanding CHF 200 million convertible bonds maturing in 2025 (CB 2025; ISIN CH0426820350), and CHF 600 million convertible bonds maturing in 2028 (CB 2028; ISIN CH1128004079) (the Repurchase Offer). The Repurchase Offer is part of a larger holistic restructuring, as announced in a press release on February 26, 2025, and an update published on May 21, 2025. To date, bondholders holding approximately 87.5% of the aggregate nominal value of the CB 2025 and approximately 90.1% of the aggregate nominal value of the CB 2028 have entered a legally binding lockup agreement in support of the holistic restructuring, including the Repurchase Offer. Such bondholders have committed to participating in the Repurchase Offer and to tender their CB 2025 and/or CB 2028 holdings. The main offer period of the Repurchase Offer is expected to start on July 10, 2025, and end at 17:30 hrs CEST on August 7, 2025. The Repurchase Offer is subject to certain offer conditions, as set out in the repurchase notice in relation to the Repurchase Offer (such notice, together with the other Repurchase Offer documentation (if any), the Repurchase Offer Documentation). These include a minimum acceptance rate condition, whereby at least 85% of the total issued nominal value of the CB 2025 and the CB 2028 must be validly tendered by the end of the main offer period of the Repurchase Offer. Bondholders can access the Repurchase Offer Documentation, including further information and instructions at the following link: www.idorsia.com/exchange-offer. Bondholders can participate in the Repurchase Offer and tender their CB 2025 and/or CB 2028 holdings via Kroll Issuer Services Ltd (the Agent) at the following link: https://deals.is.kroll.com/idorsia. Under the same link, eligible bondholders can (i) also participate in the new money facility via our Agent and (ii) find the eligibility criteria for participating in the new money facility. Further details regarding the interaction between participation in the new money facility and the Repurchase Offer can be found in the Repurchase Offer Documentation. Notes to the editor and legal notes About IdorsiaIdorsia Ltd is reaching out for more – we have more passion for science, we see more opportunities, and we want to help more patients. The purpose of Idorsia is to challenge accepted medical paradigms, answering the questions that matter most. To achieve this, we will discover, develop, and commercialize transformative medicines – either with in-house capabilities or together with partners – and evolve Idorsia into a leading biopharmaceutical company, with a strong scientific core. Headquartered near Basel, Switzerland – a European biotech hub – Idorsia has a highly experienced team of dedicated professionals, covering all disciplines from bench to bedside; QUVIVIQ™ (daridorexant), a different kind of insomnia treatment with the potential to revolutionize this mounting public health concern; strong partners to maximize the value of our portfolio; a promising in-house development pipeline; and a specialized drug discovery engine focused on small-molecule drugs that can change the treatment paradigm for many patients. Idorsia is listed on the SIX Swiss Exchange (ticker symbol: IDIA). For further information, please contact:Investor & Media RelationsIdorsia Pharmaceuticals Ltd, Hegenheimermattweg 91, CH-4123 Allschwil+41 58 844 10 10investor.relations@idorsia.com – media.relations@idorsia.com – www.idorsia.com Legal Notice and InformationThe above information contains or may contain certain "forward-looking statements", relating to the company's business, which can be identified by the use of forward-looking terminology such as "estimates", "believes", "expects", "may", "are expected to", "will", "will continue", "should", "would be", "seeks", "pending" or "anticipates" or similar expressions, or by discussions of strategy, plans or intentions. Such statements include descriptions of the company's investment and research and development programs and anticipated expenditures in connection therewith, descriptions of new products expected to be introduced by the company and anticipated customer demand for such products and products in the company's existing portfolio. Such statements reflect the current views of the company with respect to future events and are subject to certain risks, uncertainties and assumptions. Many factors could cause the actual results, performance or achievements of the company to be materially different from any future results, performances or achievements that may be expressed or implied by such forward-looking statements. Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove incorrect, actual results may vary materially from those described herein as anticipated, believed, estimated or expected. The information contained in this media release is for information purposes only and does not constitute, or form part of, an offer or invitation to purchase, sell, exchange or issue, or a solicitation of an offer to sell, purchase, exchange or subscribe to, any securities of Idorsia Ltd or Idorsia Investments SARL, including without limitation the CB 2025 and the CB 2028, or any other person, nor shall it form the basis of, or be relied upon in connection with, any contract therefor. This media release is not part of the Repurchase Offer Documentation in relation to the Repurchase Offer. Terms and conditions of the Repurchase Offer have been and/or will be published in the Repurchase Offer Documentation. Holders of CB 2025 and/or CB 2028 are urged to read the Repurchase Offer Documentation, which is and/or will be available at www.idorsia.com/exchange-offer. This media release is not a financial product or investment advice, nor is it a recommendation to acquire, exchange or dispose of securities or accounting, legal or tax advice. It has been prepared without taking into account the objectives, legal, financial or tax situation and needs of individuals. Before making any investment decision, individuals should read the Repurchase Offer Documentation and consider the appropriateness of the information having regard to their own objectives, legal, financial and tax situation and needs and seek legal, tax and other advice as appropriate for their individual needs and jurisdiction. Offer RestrictionsThis media release is only intended for distribution to non-U.S. persons (within the meaning of Regulation S under the U.S. Securities Act of 1933, as amended). This media release is not an offer to tender securities or an offer of securities. The Repurchase Offer is being made on the basis of the Repurchase Offer Documentation only and is subject to the restrictions described therein. The Repurchase Offer is not being made, and will not be made, directly or indirectly in or into, or by use of the mails of, or by any means or instrumentality of interstate or foreign commerce of, or of any facilities of a national securities exchange of, the United States. This includes, but is not limited to, facsimile transmission, electronic mail, telex, telephone, the internet and other forms of electronic communication. Attachment Press Release PDF
French Consumer Confidence Holds Steady in June, Remaining Unchanged at 88 - ForexTV
In a climate of economic caution and uncertainty, French consumer confidence has remained unchanged for a second consecutive month. According to the latest figures released on June 25, 2025, the consumer confidence indicator in France held steady at 88 in June, the same level it reached in May 2025.This stagnation reflects a persistent wariness among French consumers, despite various economic stimuli and policy measures aimed at spurring consumer spending and economic recovery. The unchanged figure may suggest a continued hesitance among households to increase their expenditure, potentially due to inflation concerns or economic uncertainty both domestically and globally.Economists are closely monitoring these indicators, as consumer confidence is a crucial measure of the economic outlook. With the French government and market players analyzing the forces behind these numbers, all eyes remain on the forthcoming months to see whether any substantial shifts in consumer sentiment will occur, which could signal a turn in economic momentum. The consistency in this key metric underscores the challenges still facing France's economy as it navigates a complex landscape of opportunities and threats.The material has been provided by InstaForex Company - www.instaforex.com
Novartis announces expiration of Regulus Therapeutics tender offer - ForexTV
Basel, June 25, 2025 – Novartis today announced that its previously announced tender offer (the “Offer”) by Redwood Merger Sub Inc., a Delaware corporation and an indirect wholly owned subsidiary of Novartis (“Purchaser”), to acquire all of the outstanding shares of common stock, par value $0.001 per share (the “Shares”), of Regulus Therapeutics Inc. (“Regulus”), in exchange for (i) $7.00 in cash per share, subject to any applicable withholding and without interest thereon, plus (ii) one contingent value right (each, a “CVR”) per Share, representing the right to receive one contingent payment of $7.00 in cash, subject to any applicable withholding and without interest thereon, upon the achievement of a regulatory milestone, expired at one minute past 11:59 p.m., New York City Time, on June 24, 2025 (the “Expiration Time”). Computershare Trust Company, N.A., the depositary for the Offer, has advised that, as of the Expiration Time, approximately 56,374,397 Shares were validly tendered and not validly withdrawn pursuant to the Offer, representing approximately 74.49% of the issued and outstanding Shares immediately prior to the Expiration Time. The parties expect the transaction to close on June 25, 2025, promptly following the acceptance of all Shares validly tendered and not validly withdrawn pursuant to the Offer. Additional Information This press release is neither an offer to purchase nor a solicitation of an offer to sell any Shares or any other securities. At the time the tender offer described in this press release was commenced, Novartis and Purchaser filed a tender offer statement on Schedule TO, including an offer to purchase, a letter of transmittal and related documents, with the U.S. Securities and Exchange Commission (the “SEC”), and Regulus filed a solicitation/recommendation statement on Schedule 14D-9 with the SEC, in each case with respect to the tender offer. An offer to purchase the Shares is only being made pursuant to the offer to purchase, the letter of transmittal and related offer documents filed as a part of the Schedule TO. Those materials and all other documents filed by, or caused to be filed by, Novartis, Purchaser and Regulus with the SEC are available at no charge on the SEC’s website at www.sec.gov/ or by directing such requests to the information agent for the offer, which is named in the tender offer statement. The offer to purchase and related materials also may be obtained for free under the “Investors – Financial Data” section of Novartis website at www.novartis.com/investors/financial-data/sec-filings. The solicitation/recommendation statement also may be obtained for free under the “Investors” section of Regulus’ website at ir.regulusrx.com/overview. In addition, Regulus files annual, quarterly and current reports and other information, and Novartis files annual reports and other information with the SEC, which are also available to the public at no charge at www.sec.gov. Disclaimer This press release contains statements that are not statements of historical fact, or “forward-looking statements,” including with respect to Novartis’ proposed acquisition of Regulus. Forward-looking statements can generally be identified by words such as “potential,” “can,” “will,” “plan,” “may,” “could,” “would,” “expect,” “anticipate,” “look forward,” “believe,” “committed,” “investigational,” “pipeline,” “launch,” or similar terms, or by express or implied discussions regarding potential marketing approvals, new indications or labeling for farabursen, regarding the proposed acquisition of Regulus and the expected timetable for completing the proposed acquisition, the benefits sought to be achieved in the proposed acquisition, or regarding potential future revenues from farabursen. You should not place undue reliance on these statements. Such forward-looking statements are based on Novartis’ current beliefs and expectations regarding future events and are subject to significant known and unknown risks and uncertainties. Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove incorrect, actual results may vary materially from those set forth in the forward-looking statements. There can be no guarantee that farabursen clinical trials will be successful, that farabursen will be submitted for marketing approval or approved for sale or, if approved, receive approval for any additional indications or labeling, in any market, or at any particular time, nor can there be any guarantee that, if approved, farabursen will be commercially successful in the future. Neither can there be any guarantee that the conditions to the closing of the proposed acquisition will be satisfied on the expected timetable or at all or that the expected benefits or synergies from this transaction will be achieved in the expected timeframe, or at all. In particular, expectations regarding farabursen or the transaction described in this press release could be affected by, among other things, the timing of the offer and the satisfaction of customary closing conditions, including the receipt of regulatory approvals on acceptable terms or at all; the risk that competing offers or acquisition proposals will be made; uncertainty as to whether the milestone associated with the CVR will be achieved and that holders of CVRs will receive payments in respect thereof; the effects of disruption from the transactions contemplated by the merger agreement and the impact of the announcement and pendency of the transactions on Novartis and/or Regulus’ businesses, including their relationships with employees, business partners or governmental entities; the risk that the offer or the merger may be more expensive to complete than anticipated; the risk that stockholder litigation in connection with the offer or the merger may result in significant costs of defense, indemnification and liability; a diversion of management’s attention from ongoing business operations and opportunities as a result of the offer, the merger or otherwise; general industry conditions and competition; general political, economic and business conditions, including interest rate and currency exchange rate fluctuations; the uncertainties inherent in research and development, including clinical trial results and additional analysis of existing clinical data; regulatory actions or delays or government regulation generally; global trends toward health care cost containment, including government, payor and general public pricing and reimbursement pressures and requirements for increased pricing transparency; our ability to obtain or maintain proprietary intellectual property protection; the particular prescribing preferences of physicians and patients; general political, economic and business conditions; safety, quality, data integrity or manufacturing issues; potential or actual data security and data privacy breaches, or disruptions of our information technology systems, and other risks and factors referred to in Novartis AG’s and Regulus’ filings and reports with the SEC, including Novartis AG’s Annual Report on Form 20-F for the year ended December 31, 2024, Regulus’ Annual Report on Form 10-K for the year ended December 31, 2024, Quarterly Report on Form10-Q for the quarter ended March 31, 2025 and any subsequent filings made by either party with the SEC, available on the SEC’s website at www.sec.gov. Novartis is providing the information in this press release as of this date and Novartis does not undertake any obligation to update any forward-looking statements contained in this press release as a result of new information, future events or otherwise, except to the extent required by law. About Novartis Novartis is an innovative medicines company. Every day, we work to reimagine medicine to improve and extend people’s lives so that patients, healthcare professionals and societies are empowered in the face of serious disease. Our medicines reach nearly 300 million people worldwide. Reimagine medicine with us: Visit us at https://www.novartis.com and connect with us on LinkedIn, Facebook, X/Twitter and Instagram. # # # Novartis Media RelationsE-mail: media.relations@novartis.com Novartis Investor RelationsCentral investor relations line: +41 61 324 7944E-mail: investor.relations@novartis.com
Aussie Stocks Nearly Flat on Softer CPI Print - ForexTV
On Wednesday, the S&P/ASX 200 hovered around the 8,555 mark, stabilizing after a robust 1% uptick in the previous session. Gains in the banking sector were tempered by declines in mining and energy stocks. Investors were keenly anticipating the forthcoming Australian inflation data, which is expected to offer insights into the Reserve Bank of Australia's future monetary policy. The RBA's next interest rate decision is expected on July 8, and current market sentiment suggests an 89% probability of a 25-basis-point reduction. Additionally, there was growing optimism regarding a tentative US-mediated ceasefire between Israel and Iran, which is currently holding. Nonetheless, there remains a sense of caution due to uncertainties surrounding the ceasefire's longevity. On the corporate landscape, the mining and gold sectors faced a 1.3% downturn, attributed to declining iron ore and gold prices. Energy stocks also saw a decline for the second consecutive session, influenced by dropping oil prices. In contrast, the financial sector saw growth, with CBA appreciating by 1% to attain a new record high.The material has been provided by InstaForex Company - www.instaforex.com
WatchGuard Launches Total MDR to Deliver Full-Stack AI-Driven Security to MSPs Within One Platform - ForexTV
WatchGuard Total MDR brings endpoint, firewall, identity, network, and cloud security into a single portal, delivering real-time, 24/7, AI-driven protection against threats across hybrid environments.SEATTLE, June 24, 2025 (GLOBE NEWSWIRE) -- WatchGuard® Technologies, a global leader in unified cybersecurity for managed service providers (MSPs), today announced WatchGuard Total MDR, a fully integrated, AI-powered managed detection and response (MDR) service. It delivers enterprise-grade security, specifically for WatchGuard endpoint, identity, network, and third-party Cloud applications, allowing partners to detect complex attacks and respond quickly, all from one platform. Total MDR minimizes noise, saves time, and shows MSPs a clearer view of threats while actively stopping attacks across the entire WatchGuard environment. As organizations adopt cloud-first models, their cybersecurity needs are mounting, confronting increasingly sophisticated, multi-vector threats that traditional detection methods are too slow and reactive to catch. This leads to a higher risk of breaches, escalating recovery costs, and increased pressure on their already limited IT teams, jeopardizing their business and reputation. WatchGuard Total MDR addresses these challenges with its 24/7 Security Operations Center (SOC) team, powered by AI and expert threat hunters. Total MDR reduces detection and response times to an average of six minutes—an 80% decrease from the industry average of 30 minutes—with fewer than one false positive per month on average compared to the typical 250+ false positives a month. Total MDR streamlines operations, including the onboarding process, lowers costs, and ensures partners deliver measurable cybersecurity outcomes across hybrid ecosystems. “WatchGuard Total MDR leverages the WatchGuard product stack to proactively stop threats that traditional tools often miss, a critical advantage for MSPs who struggle with the time-consuming and error-prone process of responding to attacks across disparate portals and vendors,” said Andrew Young, Chief Product Officer at WatchGuard. “A single-pane-of-glass view is game-changing for partners. Whether it involves blocking risky logins, isolating compromised devices, or halting suspicious network traffic, Total MDR allows MSPs to spend less time navigating different tools and more time enhancing their security posture.” The Total MDR Difference - WatchGuard Total MDR provides MSPs with a combination of technology, service, and automation, tailored to meet businesses’ unique needs and operational reality. WatchGuard Total MDR provides MSPs: The Opportunity to Save Time and Scale with Outsourced Support: Total MDR frees up MSPs' time with managed detection and response across the entire WatchGuard stack that is powerful, precise, and accessible, helping them grow and scale their business faster. Efficient Threat Management: AI-driven threat management cuts false positives to less than one per month, reducing alert fatigue, with critical threats addressed in under six minutes. Plus, proven low noise ratio in MITRE 2024, an industry-recognized cybersecurity benchmark.Expert Guidance: Total MDR is a fully managed detection and response service built for partners. It includes 24/7 SOC coverage and access to technical account managers who offer ongoing threat insights, escalation support, and adaptable runbooks to deliver the right level of guidance to match partners' services and business models.Accessible Pricing: MSPs will receive affordable, transparent pricing with enterprise-grade capabilities that include advanced features without hidden costs. Total MDR is competitively priced and easy to license, making it a perfect fit for small businesses (SMBs) and budget-conscious buyers.Quick Onboarding: This solution is built specifically for partners serving SMB and midmarket clients and ensures a streamlined onboarding process without the complexity of deep technical management and delivers faster time to value. Partners also receive access to technical account managers who stay involved following deployment to provide ongoing threat intelligence and strategic support. “The cybersecurity threat landscape is only becoming more advanced, creating gaps and concerns about potential vulnerabilities to rapid attacks. Standard SOC offerings are usually tailored for large enterprises and are not a fit for the economic reality of small businesses (SMBs),” said Julien Perret, Founder of Eiffie. “WatchGuard Total MDR is not only important for our clients, but it’s imperative as it acts as a customized virtual SOC, providing continuous threat intelligence, strategic guidance, and escalation support, enabling us to proactively defend against adversaries and attacks at an optimized cost.” WatchGuard Total MDR manages and leverages existing WatchGuard Endpoint Detection and Response (EDR), Endpoint Protection, Detection, and Response (EPDR), Advanced Endpoint Protection, Detection, and Response (AEPDR), Firebox firewalls, AuthPoint identity controls, and Network Detection & Response (NDR), all within a single portal for unified visibility and faster action. It also supports third-party cloud environments, including Microsoft 365/Azure, AWS CloudTrail, and Google Workspace. Total MDR is a key milestone following WatchGuard’s acquisition of ActZero in January of this year. ActZero’s 24/7 MDR service and experts power the WatchGuard MDR product line, which includes AI-driven security and flexible support tailored to MSPs. In the near future, WatchGuard will introduce an open model designed to meet partners where they are by enabling the integration of third-party technologies and additional tools to extend detection and response across more attack surfaces. This news also follows WatchGuard’s recent launch of FireCloud Internet Access for hybrid SASE environments and numerous industry honors. WatchGuard’s AuthPoint MFA product was named Best Authentication Technology by SC Media in 2025 and a Champion in the Canalys Cybersecurity Leadership Matrix for the third consecutive year. Just prior to that, the 2025 Cyber Defense Awards recognized WatchGuard MDR for The Most Promising Managed Detection and Response (MDR) solution, with its Zero-Trust Application Service named the Editor’s Choice Zero Trust category recipient this year. WatchGuard received recognition in 2024 from the IT Awards, ChannelVision, Fortress Cybersecurity, and TMCnet for its security solutions, and continues to lead the industry in security innovation to offer MSPs more scalable, ready-to-sell solutions that drive revenue. About WatchGuard TechnologiesWatchGuard® Technologies, Inc. is a global leader in unified cybersecurity. Our Unified Security Platform® is uniquely designed for managed service providers to deliver world-class security that increases their business scale and velocity while also improving operational efficiency. Trusted by more than 17,000 security resellers and service providers to protect more than 250,000 customers, the company’s award-winning products and services span network security and intelligence, advanced endpoint protection, multi-factor authentication, and secure Wi-Fi. Together, they offer five critical elements of a security platform: comprehensive security, shared knowledge, clarity & control, operational alignment, and automation. The company is headquartered in Seattle, Washington, with offices throughout North America, Europe, Asia Pacific, and Latin America. To learn more, visit WatchGuard.com. For additional information, promotions, and updates, follow WatchGuard on Instagram, X.com (@WatchGuard), Facebook, or LinkedIn. Also, visit our InfoSec blog, Secplicity, for real-time information about the latest threats and how to cope with them. Subscribe to The 443 – Security Simplified podcast wherever you find your favorite podcasts. WatchGuard is a registered trademark of WatchGuard Technologies, Inc. All other marks are property of their respective owners. CONTACT: Anthony Cogswell WatchGuard Technologies, Inc anthony.cogswell@watchguard.com
Bitcoin Could Spike to $120K, Here Are 4 Factors Boosting the Case for a BTC Bull Run - ForexTV
Multiple analysts have repeatedly pointed to $120,000 as bitcoin’s BTC $105,481.42 price target this year. Recent developments have strengthened that bullish case, driven by four key factors: the spot … Read Full Story
Fuse Identities launches biometric physical access card powered by FPC’s advanced T-Shape sensor - ForexTV
Gothenburg, Sweden and Oslo, Norway – June 24, 2025 – Fingerprint Cards AB (FPC), a global leader in biometric authentication technologies, is excited to announce that its partner, Fuse Identities, has launched its latest product, a cutting-edge biometric physical access card, equipped with the advanced FPC 1323 T-Shape sensor. This breakthrough solution delivers a new standard of secure, contactless identity verification for modern access control systems. The new biometric access card is fully compatible with MIFARE Classic®, MIFARE DESFire®, and HID iCLASS® technologies, making it a seamless upgrade for organizations seeking to enhance security while maintaining system interoperability. Designed with versatility in mind, the card supports high-assurance authentication without compromising user convenience. Availability and Target Markets The biometric card will be commercially available starting July 2025, and is tailored for three key segments: Critical Infrastructure: Enhancing perimeter and facility security in energy, water, transportation, and other essential services.Enterprise: Providing robust, convenient access for corporate campuses, data centers, and high-security facilities.Temporary Identity for Immigrants: Supporting secure, verifiable identification for temporary residents and immigrants in Denmark, where ensuring identity integrity is a national priority. Fuse Identities’ new card offers enhanced privacy by ensuring all biometric data is stored and matched securely on the card, not in a central database, aligning with GDPR and global privacy regulations. Adam Philpott, CEO at FPC, said:“This launch by Fuse Identities is another clear signal that biometric access cards are gaining momentum in the market. We’re proud to see our T-Shape sensor in another smart card product, powering Fuse Identities’ innovative solution, which not only improves security and user experience but also showcases the growing adoption of biometrics for access. Our partnerships are proving that biometric smart cards for access are no longer futuristic—they’re becoming the new standard.” Kim Humborstad, CEO at Fuse Identities commented:“At Fuse Identities, we’re committed to making safeguarding identity both practical and future-ready. Our collaboration with Fingerprint Cards has been key to achieving that vision—integrating their proven T-Shape sensor into our biometric access card has strengthened both performance and trust. FPC’s leadership in biometric innovation has enabled us to deliver an efficient solution that directly addresses clear market demands.” For more information about FPC and Fuse Identities, please visit www.fpc.com and www.fuseidentities.com. For further information, please contact:Adam Philpott, President & CEO Investor Relations: +46(0)10-172 00 10, investrel@fpc.com Press: +46(0)10-172 00 20, press@fpc.com About FPCFingerprint Cards AB (FPC) is a global biometrics leader, offering intelligent edge to cloud biometrics. We envision a secure, seamless world where you are the key to everything. Our solutions – trusted by enterprises, fintechs, and OEMs – power hundreds of millions of products, enabling billions of secure, convenient authentications daily across devices, cards, and digital platforms. From consumer electronics to cybersecurity and enterprise, our cloud-based identity management platforms support multiple biometric modalities, including fingerprints, iris, facial, and more. With improved security and user experience, we are driving the world to passwordless. Discover more at our website and follow us on LinkedIn and X for the latest updates. FPC is listed on Nasdaq Stockholm (FING B). About Fuse IdentitiesFuse Identities develops next-generation secure identity solutions for physical and digital environments. The company leverages best-in-class technology and deep market insight to provide high-trust, user-friendly solutions across government and enterprise sectors. Attachment 250624 - Fuse Identities
Pharming Group to host webcast on findings of a new study published in Cell advancing functional classification of variants of uncertain significance (VUS) to improve APDS diagnosis - ForexTV
For media and investors only Researchers identified variants which may cause activated phosphoinositide 3-kinase delta (PI3Kδ) syndrome (APDS)Results enable clinical genetic testing labs to appropriately reclassify VUSs, accelerating the path to a definitive APDS diagnosis for many patientsFindings reveal APDS may be more prevalent than previously estimatedWebcast to take place on Monday, June 30, 2025, at 16:30 CEST / 10:30 EDT Leiden, the Netherlands, June 24, 2025: Pharming Group N.V. (“Pharming” or “the Company”) (EURONEXT Amsterdam: PHARM/Nasdaq: PHAR) announces it will host a webcast for investors and analysts featuring Joshua Milner, MD, an internationally renowned immunologist, to discuss the findings of a recent study published in the peer-reviewed journal Cell. The study titled “Scalable generation and functional classification of genetic variants in inborn errors of immunity for improved clinical diagnosis and management” was led by Zachary Walsh, MD/PhD candidate, Dr. Milner and Benjamin Izar, MD, PhD of Columbia University. The publication details significant advances in diagnosing inborn errors of immunity, also known as primary immune disorders. The researchers’ approach helps resolve a major limit to interpretation of genetic testing that often yields variants of uncertain significance (VUS) when evaluating such disorders, including activated phosphoinositide 3-kinase delta (PI3Kδ) syndrome (APDS). There are currently over 1,300 known U.S. patients with a VUS in the PIK3CD and PIK3R1 genes implicated in APDS. The team at Columbia introduced more than 2,000 PIK3CD/PIK3R1 variants, representing a portion of all potential variants, into human T-cell lines and assessed PI3Kδ pathway activity. These studies successfully confirmed known disease-causing APDS variants and, importantly, also identified over 100 new variants with evidence for PI3Kδ pathway hyperactivity. By analyzing very large datasets of patients who agreed to have their genetic testing linked to their medical records, the research team at Columbia concludes that the real prevalence of APDS may be higher than previously estimated. During the call, Dr. Milner will provide insights into the study’s methodology, key findings, implications, and next steps. Anurag Relan, Pharming Chief Medical Officer, will lead a Q&A session with Dr. Milner and discuss next steps to collaborate with genetic testing laboratories on their VUS reclassification efforts, extend the study to assess additional variants, and further investigate the clinical phenotype of APDS in the newly identified variants. Anurag Relan, MD, MPH, Chief Medical Officer of Pharming, commented: “This important study, recently published in Cell, is a key step towards providing answers to patients with a VUS in the PIK3CD or PIK3R1 genes. The study highlights the importance of increased genetic screening and awareness to ensure timely diagnosis of APDS. We expect these data to enable clinical genetic testing laboratories to reclassify a portion of the VUSs, accelerating the path to a definitive APDS diagnosis for many patients. We look forward to additional near-term studies to facilitate the reclassification of the remaining VUSs and to further exploring the prevalence and phenotype of this rare disease.” Dr Joshua Milner, MD, Director Division of Pediatric Allergy, Immunology and Rheumatology at Columbia University Irving Medical Center, commented: “This study offers a powerful new lens for interpreting VUSs and uncovering therapeutic insights in conditions like APDS. We hope these findings will support clinicians in making more informed decisions and ultimately lead to better outcomes for patients navigating rare immune disorders.” Note: This study was supported by a National Institutes of Health (NIH)/National Cancer Institute (NCI) grant and was in part supported through a sponsored research agreement with Pharming. The webcast will take place on Monday, June 30, 2025, at 16:30 CEST / 10:30 EDT. To participate, please register at https://edge.media-server.com/mmc/p/q6x83at2. Questions can be submitted in advance, via email to investor@pharming.com. For more information and to access the full peer-reviewed study in Cell, please visit https://www.cell.com/cell/abstract/S0092-8674(25)00624-5. About Activated Phosphoinositide 3-Kinase δ Syndrome (APDS) APDS is a rare primary immunodeficiency that was first characterized in 2013. APDS is caused by variants in either one of two identified genes known as PIK3CD or PIK3R1, which are vital to the development and function of immune cells in the body. Variants of these genes lead to hyperactivity of the PI3Kδ (phosphoinositide 3-kinase delta) pathway, which causes immune cells to fail to mature and function properly, leading to immunodeficiency and dysregulation1,2,3 APDS is characterized by a variety of symptoms, including severe, recurrent sinopulmonary infections, lymphoproliferation, autoimmunity, and enteropathy.4,5 Because these symptoms can be associated with a variety of conditions, including other primary immunodeficiencies, it has been reported that people with APDS are frequently misdiagnosed and suffer a median 7-year diagnostic delay.6 As APDS is a progressive disease, this delay may lead to an accumulation of damage over time, including permanent lung damage and lymphoma.4-7 A definitive diagnosis can be made through genetic testing. APDS affects approximately 1 to 2 people per million worldwide. About leniolisibLeniolisib is an oral small molecule phosphoinositide 3-kinase delta (PI3Kẟ) inhibitor approved in the U.S., U.K., Australia and Israel as the first and only targeted treatment of activated phosphoinositide 3-kinase delta (PI3Kδ) syndrome (APDS) in adult and pediatric patients 12 years of age and older. Leniolisib inhibits the production of phosphatidylinositol-3-4-5-trisphosphate, which serves as an important cellular messenger and regulates a multitude of cell functions such as proliferation, differentiation, cytokine production, cell survival, angiogenesis, and metabolism. Results from a randomized, placebo-controlled Phase III clinical trial demonstrated statistically significant improvement in the coprimary endpoints, reflecting a favorable impact on the immune dysregulation and deficiency seen in these patients, and interim open label extension data has supported the safety and tolerability of long-term leniolisib administration.8,9 Leniolisib is currently under regulatory review in the European Economic Area, Canada and several other countries for APDS, with plans to pursue regulatory approval in Japan. Leniolisib is also being evaluated in two Phase III clinical trials in children with APDS and in two Phase II clinical trials in primary immunodeficiencies (PIDs) with immune dysregulation. The safety and efficacy of leniolisib has not been established for PIDs with immune dysregulation beyond APDS. About Pharming Group N.V. Pharming Group N.V. (EURONEXT Amsterdam: PHARM/Nasdaq: PHAR) is a global biopharmaceutical company dedicated to transforming the lives of patients with rare, debilitating, and life-threatening diseases. We are commercializing and developing a portfolio of innovative medicines, including small molecules and biologics. Pharming is headquartered in Leiden, the Netherlands, and has employees around the globe who serve patients in over 30 markets in North America, Europe, the Middle East, Africa, and Asia-Pacific. For more information, visit www.pharming.com and find us on LinkedIn. Forward-Looking Statements This press release may contain forward-looking statements. Forward-looking statements are statements of future expectations that are based on management’s current expectations and assumptions and involve known and unknown risks and uncertainties that could cause actual results, performance, or events to differ materially from those expressed or implied in these statements. These forward-looking statements are identified by their use of terms and phrases such as “aim”, “ambition”, ‘‘anticipate’’, ‘‘believe’’, ‘‘could’’, ‘‘estimate’’, ‘‘expect’’, ‘‘goals’’, ‘‘intend’’, ‘‘may’’, “milestones”, ‘‘objectives’’, ‘‘outlook’’, ‘‘plan’’, ‘‘probably’’, ‘‘project’’, ‘‘risks’’, “schedule”, ‘‘seek’’, ‘‘should’’, ‘‘target’’, ‘‘will’’ and similar terms and phrases. Examples of forward-looking statements may include statements with respect to timing and progress of Pharming's preclinical studies and clinical trials of its product candidates, Pharming's clinical and commercial prospects, and Pharming's expectations regarding its projected working capital requirements and cash resources, which statements are subject to a number of risks, uncertainties and assumptions, including, but not limited to the scope, progress and expansion of Pharming's clinical trials and ramifications for the cost thereof; and clinical, scientific, regulatory, commercial, competitive and technical developments. In light of these risks and uncertainties, and other risks and uncertainties that are described in Pharming's 2024 Annual Report and the Annual Report on Form 20-F for the year ended December 31, 2024, filed with the U.S. Securities and Exchange Commission, the events and circumstances discussed in such forward-looking statements may not occur, and Pharming's actual results could differ materially and adversely from those anticipated or implied thereby. All forward-looking statements contained in this press release are expressly qualified in their entirety by the cautionary statements contained or referred to in this section. Readers should not place undue reliance on forward-looking statements. Any forward-looking statements speak only as of the date of this press release and are based on information available to Pharming as of the date of this release. Pharming does not undertake any obligation to publicly update or revise any forward-looking statement as a result of new information, future events or other information. References Lucas CL, et al. Nat Immunol. 2014;15(1):88-97.Elkaim E, et al. J Allergy Clin Immunol. 2016;138(1):210-218.Nunes-Santos C, Uzel G, Rosenzweig SD. J Allergy Clin Immunol. 2019;143(5):1676-1687. Coulter TI, et al. J Allergy Clin Immunol. 2017;139(2):597-606.Maccari ME, et al. Front Immunol. 2018;9:543.Jamee M, et al. Clin Rev Allergy Immunol. 2020 Dec;59(3):323-333.Condliffe AM, Chandra A. Front Immunol. 2018;9:338.Rao VK, et al Blood. 2023 Mar 2;141(9):971-983.Rao VK, et al. J Allergy Clin Immunol 2024;153:265-74. For further public information, contact:Pharming Group, Leiden, the NetherlandsMichael Levitan, VP Investor Relations & Corporate CommunicationsT: +1 (908) 705 1696E: investor@pharming.com FTI Consulting, London, UKSimon Conway/Alex Shaw/Amy ByrneT: +44 203 727 1000 LifeSpring Life Sciences Communication, Amsterdam, the NetherlandsLeon MelensT: +31 6 53 81 64 27E: pharming@lifespring.nl US PRChristina SkrivanT: +1 (636) 352-7883E: Christina.Skrivan@precisionaq.com Attachment Pharming to host webcast on study published in Cell on VUSs_EN_24JUN25
Hapbee Technologies Inc. Closes 2024 with Record Q4 Device Sales, Global Distribution Partnerships and Strategic Board Appointments - ForexTV
Fueled by a 198% surge in Q4 device sales revenue and a 200% increase in shipments, Hapbee’s revitalized marketing strategy, expanded retail footprint, luxury spa partnerships, and high-profile Board additions have set the stage for accelerated growth heading into 2025. VANCOUVER, British Columbia, June 24, 2025 (GLOBE NEWSWIRE) -- Hapbee Technologies Inc. (TSXV: HAPB | OTCQB: HAPBF), (“Hapbee” or the “Company”), the digital wellness technology company pioneering the science of bio-streaming, is pleased to announce the financial and operational results for the fiscal year ending December 31, 2024. In 2024, Hapbee executed a bold strategic reset anchored by two private placement rounds, a revitalized ambassador program, and three new additions to its Board of Directors which propelled a record surge in Q4 device shipments and revenues, marking a pivotal inflection point in the Company’s commercial trajectory. Device Sales & Revenue: Q4 marked a breakout period, with device sales revenue soaring 198% and unit shipments doubling quarter-over-quarter fueled by elevated customer engagement, improved product education, and growing brand visibility. - Ambassador-Led Marketing: A targeted ambassador engagement strategy and high-impact digital campaigns funded by private placements in Q2 and Q3 amplified Hapbee’s brand presence and ignited consumer demand across digital and social channels. - Retail Expansion: Hapbee products are now available in 380+ Target stores nationwide and online at Target.com, reinforcing broad consumer access and strengthening the retail distribution network. - Luxury Wellness Partnership: The launch of a collaboration with Jumeirah Group integrated Hapbee’s products into premier spa wellness programs, with plans underway to expand into additional Jumeirah properties globally. - Enhanced Sleep Solutions: Introduction of a new, entry-level Smart Sleep Membership at a more accessible price point ($10/month or $99/yr) aligned with the recently launched Smart Sleep Pad broadens the Company’s sleep-wellness offering for sleep-focused consumers. - Platform & Product Investments: Capital and resources were allocated to develop a next-generation mobile app and redesign the website, designed to deliver seamless user experiences, personalized features, and new subscription revenue channels in 2025. - Board Strengthening: Hapbee welcomed NBA All-Star Jaylen Brown, Chief Commercial Officer Rizwan Shah, and global business leader Abdulla Al Zain to its Board of Directors, enhancing the Company’s strategic guidance in product innovation and international expansion. “Our team executed a strategic reset in Q2 to improve product experience, brand awareness, and retail accessibility,” said Yona Shtern, CEO of Hapbee. “The Q4 results confirmed that these initiatives are yielding strong returns. We enter 2025 with significant momentum, and we look forward to the upcoming launch of our reimagined mobile app and enriched customer journey.” About Hapbee Technologies Inc.: Hapbee is a digital wellness technology company specializing in bio-streaming wearables designed to help people improve their sleep, focus, mood, and recovery. The company's mission is to put wellness into the hands of everyone, through accessible, science-backed, and non-invasive solutions. The Company's financial statements and management's discussion and analysis for the period ended December 31, 2024 are available on SEDAR+ at www.sedarplus.ca and on Hapbee's investor website at investors.hapbee.com. Learn more at www.hapbee.com Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release. Forward-Looking InformationForward-looking information is provided for the purpose of presenting information about management’s current expectations and plans relating to the future and readers are cautioned that such statements may not be appropriate for other purposes. Forward-looking information involves significant risks and uncertainties and should not be read as a guarantee of future performance or results as actual results may differ materially from those expressed or implied in such forward-looking information. Those risks and uncertainties include, among other things, risks related to: that Hapbee will be able to complete its business objectives as anticipated; Hapbee’s industry and its business, which may negatively impact, and may continue to negatively impact, Hapbee and may materially adversely affect its investments, results of operations, financial condition and Hapbee’s ability to obtain additional equity or debt financing, and satisfy its financial obligations; circumstances may change resulting in the use of proceeds; general economic conditions; future growth potential; prices of its securities; liquidity; ability to access capital markets; environmental matters; and changes in legislation or regulations. Management believes that the expectations reflected in the forward-looking information contained herein are based upon reasonable assumptions and information currently available; however, management can give no assurance that actual results will be consistent with such forward-looking information. The forward-looking information contained herein is expressly qualified in its entirety by this cautionary statement. Forward-looking information reflects management's current beliefs and is based on information currently available to Hapbee. The forward-looking information is stated as of the date of this news release and Hapbee assumes no obligation to update or revise such information to reflect new events or circumstances, except as may be required by applicable law. Investor RelationsRenmark Financial Communications Inc.Bettina Filippone: bfilippone@renmarkfinancial.comTel: (416) 644-2020 or (514) 939-3989www.renmarkfinancial.com Media RelationsTheory CommunicationsAndrea Hamilton: andrea@theorycomm.comwww.theorycomm.com
The Best Tom Yum Seafood Soup in Las Vegas in The Spotlight at Kung Fu Thai & Chinese Restaurant - ForexTV
Las Vegas, June 23, 2025 (GLOBE NEWSWIRE) -- Las Vegas, Nevada - Kung Fu Thai & Chinese Restaurant in Las Vegas is excited to share their newest menu addition: the Best Tom Yum Shrimp Soup in Las Vegas. This delicious dish adds a vibrant new flavor to their menu, showcasing a rich, authentic taste experience. Known for blending traditional Thai and Chinese dishes with fresh twists, the restaurant aims to give customers flavors they love while introducing new culinary delights. The new Tom Yum Shrimp Soup is a flavorful mix of lemongrass, lime leaves, shrimp, and an array of spices. It's not just about the bold taste; it's also about genuine cultural flavors. The soup includes jumbo shrimp, calamari, scallops, and green shell mussel-oyster, topped off with fresh cilantro and served in a classic Thai hot pot for those dine in. It's designed to immerse eaters in the authentic taste of Thailand, and it's an excellent choice whether one is dining in, going for take-out, or using their food delivery service, all of which can be conveniently accessed through their online ordering system. Alan Wong from Kung Fu Thai & Chinese Restaurant says, "We always aim to stay true to Thai culinary roots and also appeal to our customers' diverse tastes. Our new Tom Yum Shrimp Soup reflects this goal. We're confident our guests will enjoy the rich flavors and authenticity it brings." Adding this soup shows the restaurant's dedication to expanding their menu, which already includes a wide range from appetizers to desserts, plus vegetarian options. It's a thoughtful response to what customers want, offering not just satisfying meals but also introducing diners to new tastes. The restaurant believes that food can connect people, representing the cultures behind their recipes. Balancing tradition with creativity, Kung Fu Thai Chinese Restaurant continually expands its menu, prioritizing quality and choice for guests. Besides soups, they offer a variety of entrees, fried rice dishes, salads, and more, all aiming to deliver flavorful experiences. The restaurant's website provides detailed information for those eager to explore this new menu. Photos and descriptions allow potential diners to preview the wide selection they'll find before visiting the restaurant or placing an online order. With a user-friendly online system, ordering for delivery, take-out, or dine-in is simple and straightforward. Alan Wong adds, "Our goal has always been to guide patrons on a culinary journey, showcasing the rich and diverse flavors of Thai and Chinese cuisine. With this new soup, we continue that journey, offering authentic dishes alongside fresh menu additions." Kung Fu Thai Chinese Restaurant stands out in Las Vegas with its varied menu, focus on cooking authenticity, and efforts to engage customers meaningfully. Their approach to creating dishes like the Best Tom Yum Shrimp Soup offers an experience filled with cultural authenticity and culinary delight. https://www.youtube.com/watch?v=wxfsRvj8Eqs For more details on their latest menu additions and other offerings, check out their website: https://www.kungfuplaza.com/soups/soups-1/tom-yum-seafood. Visitors can find information on menu items, special offers, and ordering options, making it easy to plan an amazing dining experience. ### For more information about Kung Fu Thai & Chinese Restaurant, contact the company here:Kung Fu Thai & Chinese RestaurantAlan Wong702-247-4120aw@kungfurestaurants.com3505 S Valley View Blvd Las Vegas, NV 89103 CONTACT: Alan Wong
Norsk Hydro: Hydro's second quarter results 2025 - ForexTV
Norsk Hydro: Hydro's second quarter results 2025 Hydro's second quarter results 2025 will be released at 07:00 CEST (01:00 EDT, 06:00 BST, 05:00 UTC/GMT) on July 22, 2025. The quarterly report and presentation will be available on hydro.com at the same time as the release. President and CEO Eivind Kallevik and Executive Vice President and CFO Trond Olaf Christophersen, will host a webinar in English at 08:30 CEST the same day. There will be a Q&A session directly after the presentation. There will be no physical presentation or press conference. To join the webinar and ask questions, use the link to our webcast page. The webcast is powered by Zoom. No login or registration in advance is required. It is also possible to log in using the dial-in option: Norway +47 2400 4736 London, UK +44 330 088 5830 New York, US +1 929 205 6099 Find your local number Meeting ID: 916 4818 8026 We advise you to investigate in advance if your company has any restrictions using the Zoom platform. Investor contact: Martine Rambøl Hagen +47 91708918 martine.rambol.hagen@hydro.com
TISSIUM Receives FDA De Novo Authorization for COAPTIUM® CONNECT in Atraumatic Sutureless Peripheral Nerve Repair - ForexTV
This regulatory milestone marks TISSIUM’s entry into the U.S. market and establishes the foundation of the TISSIUM polymer platform for atraumatic tissue repair Paris, France, Cambridge, USA, June 24, 2025 - TISSIUM, a MedTech company pioneering biomorphic programmable polymers for tissue reconstruction, today announced that the U.S. Food and Drug Administration (FDA) has granted De Novo marketing authorization for COAPTIUM® CONNECT with TISSIUM Light, a first-of-its-kind atraumatic sutureless solution for peripheral nerve repair. This authorization represents a pivotal regulatory milestone for TISSIUM, further validating its biopolymer platform and enabling U.S. commercialization of its first product. COAPTIUM® CONNECT is now the only FDA-authorized system designed for atraumatic sutureless nerve coaptation. Christophe Bancel, Co-Founder and CEO of TISSIUM said: “This FDA marketing authorization validates over a decade of scientific and clinical commitment to developing next-generation solutions in tissue reconstruction. COAPTIUM® CONNECT is the first demonstration of the transformative potential of our polymer platform and an important step in making atraumatic tissue repair available to patients.” Peripheral nerve injuries affect hundreds of thousands of patients annually and are typically repaired using microsurgical sutures. However, this approach presents limitations—including technical complexity, risk of additional trauma, and variable outcomes. COAPTIUM® CONNECT addresses these challenges by offering a reproducible, atraumatic sutureless alternative that preserves nerve integrity and simplifies the coaptation process1. In a recent clinical study on 12 patients with digital nerve injuries, COAPTIUM® CONNECT achieved 100% procedural success, defined as successful atraumatic sutureless coaptation using the polymer-assisted coaptation device, with all patients regaining full flexion and extension of the injured digit and reporting no pain 12 months after the procedure1. TISSIUM plans to initiate commercial rollout of COAPTIUM® CONNECT in the coming months. The COAPTIUM® CONNECT System leverages TISSIUM’s unique biopolymer platform, invented by Maria Pereira, Jeffrey Karp and Robert Langer at the MIT and Brigham & Women’s Hospital, using its bioresorbable light-activated surgical polymer and its 3D-printed polymer chamber. Maria Pereira, Co-Founder and Chief Innovation Officer, said: “This first product illustrates the technical versatility and the potential of the TISSIUM polymer platform, not only in peripheral nerve repair where other solutions are currently under development, but also in other surgical applications, such as atraumatic hernia repair and cardiovascular sealing.” *** About TISSIUM TISSIUM is a clinical and commercial stage MedTech company based in Paris, France, Cambridge, USA, and with a manufacturing site in Roncq, France. The company is pioneering a proprietary platform of fully biosynthetic, biomorphic, programmable, elastomeric polymers designed to address critical unmet needs in atraumatic tissue repair and tissue reconstruction. TISSIUM’s diversified pipeline includes seven products across three core verticals: sutureless nerve repair, atraumatic hernia repair, and cardiovascular sealants. Each solution is designed to optimize tissue repair through controlled and consistent procedures with specialized delivery and activation devices to maximize the performance and usability of its products. Founded in 2013, TISSIUM is built on breakthrough research and intellectual property originating from the laboratories of Professor Robert Langer (MIT) and Professor Jeffrey M. Karp (Brigham and Women’s Hospital). For more information, please visit www.TISSIUM.com and follow us on LinkedIn: TISSIUM. *** Contacts Investor relationsRomain Attard – Chief Financial Officer rattard@tissium.com Press tissium@yourstorypr.com 1 A Sutureless Approach to Nerve Repair: Results from a Clinical Study in Digital Nerves, Randi Bindra, Journal of Hand Surgery, submitted 2025 Attachment 20250624 - TISSIUM_FDA DeNovo announcement
RARE FERRARI BERLINETTAS LINE UP FOR INAUGURAL BROAD ARROW ZOUTE CONCOURS AUCTION - ForexTV
AUCTION TO FEATURE A 1967 FERRARI 275 GTB/4 FINISHED IN EXTREMELY RARE VERDE PINO | HIGHLY COLLECTIBLE 1970 FERRARI 365 GTB/4 DAYTONA “PLEXI” ONE OF ONLY TWO DELIVERED NEW IN AVORIO | AUCTION TO TAKE PLACE ON 10 OCTOBER 2025 IN COLLABORATION WITH ZOUTE GRAND PRIX CAR WEEK The stunning Pino Verde 1967 Ferrari 275 GTB/4 set to star at Broad Arrow’s inaugural Zoute Concours Auction (Credit – Dennis Noten / Courtesy of Broad Arrow Auctions) The 1970 Ferrari 365 GTB/4 Daytona “Plexi” to be presented at Broad Arrow’s inaugural Zoute Concours Auction (Credit – Dennis Noten / Courtesy of Broad Arrow Auctions) LONDON, England, June 24, 2025 (GLOBE NEWSWIRE) -- Broad Arrow Auctions, a Hagerty (NYSE: HGTY) company, is excited to announce that two very special Ferrari models are among the first to be consigned for its inaugural Zoute Concours Auction on 10 October. The first is a 1967 Ferrari 275 GTB/4, estimated at €2.700.000 - €3.200.000, with incredible provenance and one of just six to be delivered from the Maranello factory in stunning Verde Pino. The second is a rare and equally stunning 1970 Ferrari 365 GTB/4 Daytona “Plexi” (Estimate: Available on request), one of only two finished in Avorio (Ivory) from new. These two Ferraris will feature in Broad Arrow’s new Zoute Concours Auction, which will be held in collaboration with Zoute Grand Prix Car Week in Belgium (8-12 October 2025). The auction will take place on Friday 10 October at the beautiful Approach Golf in Knokke-Heist, where the two Ferraris will be among 70 exceptional collector cars on offer. “To have two iconic Ferrari berlinettas with such incredible provenance and rarity already consigned to our inaugural Zoute Concours Auction is very exciting,” says Gregory Tuytens, Head of Consignments in Belgium and the Netherlands for Broad Arrow. “The provenance, condition and especially the colour scheme of both the Ferrari 275 GTB/4 and the 365 GTB/4 Daytona “Plexi” mean they hold an incredibly special place in the history of the Maranello marque and will attract a great deal of interest as particularly top-tier examples of each model.” The Ferrari 275 GTB/4 is highly sought after by discerning collectors around the world and this 1967 model is one of a mere six finished in Verde Pino (Pine Green) from the factory, a significant factor in making it one of the most collectible of all. Just 330 “four-cams” were produced, and this Ferrari Classiche certified, matching-numbers example boasts impeccable provenance. Wearing chassis number 10563, it has been meticulously cared for in world-renowned collections throughout its life. It benefits from having been refinished and retrimmed in its factory livery which includes lovely Arancio leather and it has been so well looked after that it has never required a full restoration, making it one of the most original examples available. Its provenance is further exemplified by the fact that it has matching numbers throughout, including the four-cam V12 engine, gearbox and differential, confirmed by its Ferrari Classiche certification. This incredible example of Ferrari design and engineering features Marchal headlights, Borrani wire wheels and a Blaupunkt stereo. The car comes with its original leather pouch containing its books, immaculate toolkit and jack and, naturally, its Ferrari Classiche-issued ‘Red Book’. The Ferrari 365 GTB/4 Daytona is one of the most collectible berlinettas in motoring history. Designed by Leonardo Fioravanti, its beautiful lines have proven to be timeless, ensuring its continued desirability among collectors around the world. Chassis No. 13357 is one of approximately 400 ‘Plexi’ Daytonas, so-called for the Plexiglas that spanned the nose and covered the headlights. Legislation in the United States forced Ferrari to change this design to incorporate retractable headlights, making the ‘Plexi’ models extremely collectible today. Further adding to the rarity of this 1970 model is that it is one of only two finished in beautiful Avorio from the factory. Delivered new via Jacques Swaters' famous Garage Francorchamps in Brussels, Belgium, its original owner was the Belgian racing driver, Baron Hughes “Hugh” de Fierlant, who drove for the famous Écurie Francorchamps racing team and competed successfully in the 1000km of Spa-Francorchamps and seven editions of the 24 Hours of Le Mans. This exceptional example has always remained in Belgium and its revered Colombo V12 still bears its engine number B 262. It has benefitted from a full professional restoration, including the interior, which is finished in the original factory specification of Beige Scuro leather with Nero inserts. Ferrari Classiche certification was issued for the car in 2011 and with its ‘Plexi’ nose, extremely rare colour combination and matching numbers, this Ferrari 365 GTB/4 stands out as a concours-worthy example of one of the most desirable grand tourers in Ferrari history. “The consignment of both of these rare Ferrari models shows how much interest our inaugural Zoute Concours Auction is already generating among collectors around the world,” says Joe Twyman, VP of Sales for Broad Arrow’s EMEA Region. “We are looking forward to providing more exciting news on additional consignments in the coming weeks.” Additional information on Broad Arrow’s Zoute Concours Auction is available at broadarrowauctions.com. Collectors interested in consigning or attending the auction are invited to speak with a Broad Arrow car specialist about this exciting sale. Ends. About Broad Arrow AuctionsBroad Arrow Auctions, a Hagerty (NYSE: HGTY) company, is a leading global collector car auction house. Founded in 2021 by highly experienced industry veterans, Broad Arrow offers exceptional quality cars to collectors and enthusiasts around the world. As the fastest growing auction house in its segment, Broad Arrow’s flagship annual events include The Monterey Jet Center Auction, in conjunction with Motorlux in California, The Amelia Auction, as the official auction of The Amelia (Concours d’Elegance) in Florida, and The Porsche Auction, in conjunction with Air | Water by Luftgekühlt in California. Broad Arrow expanded its global footprint in 2023, with renowned car specialists joining the team in the UK and Europe. Broad Arrow launched its first auction in Europe in May 2025 as the new official auction house of the Concorso d’Eleganza Villa d’Este in Italy in partnership with BMW AG. Broad Arrow now expands its global auction footprint with two new auctions in 2025 to be held during Zoute Grand Prix and Auto Zurich. Learn more at broadarrowauctions.com and follow us on Instagram, Facebook, LinkedIn, and Twitter. About Hagerty, Inc. (NYSE: HGTY) Hagerty is an automotive enthusiast brand committed to saving driving and to fueling car culture for future generations. The company is a leading provider of specialty vehicle insurance, expert car valuation data and insights, live and digital car auction services, immersive events and automotive entertainment custom made for the 67 million Americans who self-describe as car enthusiasts. Hagerty also operates in Canada and the U.K. and is home to Hagerty Drivers Club, a community of over 875,000 who can’t get enough of cars. For more information, please visit www.hagerty.com or connect with us on Facebook, Instagram, X and LinkedIn. About Zoute Grand Prix Car WeekZoute Grand Prix is a wondrous world of high-end lifestyle and art events, with cars as the centre of attention. The five-day festival is a gathering of passionate collectors, connoisseurs, and automotive aficionados who share a love for timeless cars and exclusivity. The event offers a diverse variety of rallies, GT tours, car and art exhibitions, and auctions. Alongside the most stunning classic and luxury cars, guests indulge in the finest gastronomy, with top chefs and premium dining experiences. Through every Zoute Grand Prix experience, guests enjoy world-class service and the warmest welcome in a setting of pure elegance. Learn more about Zoute Grand Prix at zoutegrandprix.be. Forward-Looking Statements - This press release contains statements that constitute “forward-looking statements” within the meaning of the federal securities laws. All statements provided, other than statements of historical fact, are forward-looking statements, including those regarding Hagerty’s future operating results and financial position, Hagerty’s business strategy and plans, products, services, and technology implementations, market conditions, growth and trends, expansion plans and opportunities, and Hagerty’s objectives for future operations. The words “anticipate,” “believe,” “envision,” “estimate,” “expect,” “intend,” “may,” “plan,” “predict,” “project,” “target,” “potential,” “will,” “would,” “could,” “should,” “continue,” “ongoing,” “contemplate,” and similar expressions, and the negative of these expressions, are intended to identify forward-looking statements. Hagerty has based these forward-looking statements largely on current expectations about future events, which may not materialize. Actual results could differ materially and adversely from those anticipated or implied in the forward-looking statements. These factors include, among other things, Hagerty’s ability to: (i) compete effectively within our industry and attract and retain our insurance policyholders and paid Hagerty Drivers Club (“HDC”) subscribers; (ii) maintain key strategic relationships with our insurance distribution and underwriting carrier partners; (iii) prevent, monitor, and detect fraudulent activity; (iv) manage risks associated with disruptions, interruptions, outages or other issues with our technology platforms or our use of third-party services; (v) accelerate the adoption of our membership and marketplace products and services, as well as any new insurance programs and products we offer; (vi) manage the cyclical nature of the insurance business, including through any periods of recession, economic downturn or inflation; (vii) address unexpected increases in the frequency or severity of claims, and (viii) comply with the numerous laws and regulations applicable to our business, including state, federal and foreign laws relating to insurance and rate increases, privacy, the internet, and accounting matters. The forward-looking statements herein represent the judgment of Hagerty as of the date of this release and Hagerty disclaims any intent or obligation to publicly update or review any forward-looking statement, whether as a result of new information, future developments, or otherwise. This press release should be read in conjunction with the information included in Hagerty’s other press releases, reports and other filings with the Securities and Exchange Commission. Understanding the information contained in these filings is important in order to fully understand Hagerty’s reported financial results and its business outlook for future periods. Attachments The stunning Pino Verde 1967 Ferrari 275 GTB/4 set to star at Broad Arrow’s inaugural Zoute Concours Auction The 1970 Ferrari 365 GTB/4 Daytona “Plexi” to be presented at Broad Arrow’s inaugural Zoute Concours Auction CONTACT: Ian Kelleher Broad Arrow Auctions 917-971-4008 ikelleher@hagerty.com Meghan McGrail Broad Arrow Auctions 519-365-8750 mmcgrail@hagerty.com
Thermosome Reports Encouraging Clinical Data of THE001 in Advanced Soft Tissue Sarcomas - ForexTV
Heat-triggered release mechanism unequivocally confirmedFavorable safety profile with good tolerability Signs of encouraging clinical activity in heavily pre-treated patients including meaningful progression-free survival (PFS)One participant with previously unresectable disease in DL2 underwent surgery, indicating no vital tumor cells in the target lesion Munich, Germany – June 24, 2025 – Thermosome GmbH, a clinical-stage drug development company focused on targeted tumor therapies, today announced new, encouraging data from its ongoing Phase I clinical trial evaluating its lead compound THE001 (DPPG2-TSL-DOX) in combination with regional hyperthermia (RHT) for the treatment of soft tissue sarcomas (STS). The Phase I study is assessing the safety, pharmacokinetics (PK), and preliminary efficacy of THE001 + RHT in participants with locally advanced unresectable or metastatic STS, who have exhausted all prior treatment options, including standard doxorubicin (DOX). Despite the early stage of development and a small number of participants, signs of meaningful clinical activity have emerged. Among the heavily pre-treated participants – including patients pre-treated with DOX – the median progression-free survival (PFS) following treatment with THE001 + RHT reached 4.5 months across both dose levels (20 and 40 mg/m²). This exceeds the typical median PFS of 2.7 to 3.5 months observed with first-line DOX therapy in treatment-naïve patients at DOX doses of 75 mg/m2, i.e., 2-4x higher than doses of THE001 applied in the Phase I setting. At dose level 2 (40 mg/m²), the mean PFS reached 7.1 months. Two out of three participants in this dose level achieved a partial response (PR) according to Choi criteria and completed the maximum extended treatment phase of 12 cycles (~8.3 months). Notably, one participant whose tumor was initially considered unresectable, could undergo surgical resection at the end of the extended study treatment. This participant showed a tumor shrinkage of -16% in the sum of target lesions, a partial response according to Choi criteria and no vital tumor cells in the resected target lesion. Across dose levels 1 and 2, THE001 + RHT demonstrated a favorable safety profile. There were no dose-limiting toxicities or high-grade treatment-related adverse events that led to treatment discontinuation, underscoring the good tolerability of THE001 in combination with RHT. “These findings not only provide consistent proof of the galenic concept of heat-triggered, largely complete DOX release from THE001, but also demonstrate clinical benefit in a highly challenging patient population,” said Dr. Frank Hermann, Chief Medical Officer of Thermosome. “We are particularly encouraged by the results of one participant who underwent resection after 12 full treatment cycles with THE001 and regional hyperthermia with no vital tumor cells found in the resected target lesion. These results clearly support future exploration in the neoadjuvant setting.” Alexander Eggermont, Professor of Clinical and Translational Immunotherapy, University Medical Center, Utrecht, and a member of Thermosome´s Clinical Advisory Board, commented: “The Phase I data of THE001, a thermosensitive liposomal DOX, and regional hyperthermia in heavily pre-treated DOX-experienced soft tissue sarcoma patients, particularly from dose level 2, are very encouraging. These results demonstrate the clinical potential of this highly innovative approach and provide the necessary foundation for transitioning into Phase II proof-of-concept development. I am excited to support this important work and look forward to advancing this promising therapy, which has the potential to significantly improve outcomes for patients with soft tissue sarcoma, particularly in the neoadjuvant setting.” “It is exciting to see the promising results of THE001 combined with regional hyperthermia, demonstrating strong potential to address the high unmet need for better treatments for soft tissue sarcoma,” added Prof. Shreyaskumar Patel, the Robert R. Herring Distinguished Professor of Medicine and Medical Director of the Sarcoma Center at The University of Texas MD Anderson Cancer Center, Houston Texas, and a member of Thermosome’s Clinical Advisory Board. ”Expansion into Phase II, also including the U.S., would offer a much-needed validation of this new therapeutic strategy for patients with STS. I look forward to supporting the advancement of this innovative treatment option to improve outcomes for patients here in the U.S. and globally on the back of the orphan drug designation granted by the FDA.” Considering supportive feedback from the German Federal Institute for Drugs and Medical Devices (BfArM) on the development of THE001 + RHT in the neoadjuvant setting, the available data from last-line participants are intended to support further development in the neoadjuvant setting. ### About Thermosome Thermosome is a clinical-stage drug development company focused on targeted tumor therapy combined with immune stimulation for improved cancer therapy. At its core is a novel, proprietary tumor targeting approach that allows for significantly increased local drug concentration and improved tumor penetration to achieve improved clinical treatment efficacy. The first clinical indication for its lead drug candidate THE001 is soft tissue sarcoma, where the Company aims to improve the current standard of care (free doxorubicin). Thermosome’s approach enables targeted tumor treatment independent of specific molecular targets and covers patient populations across all chemo-sensitive tumor subtypes. More information: www.thermosome.com About THE001 Thermosome’s clinical-stage lead drug candidate THE001 is a thermosensitive liposomal formulation of the chemotherapeutic drug doxorubicin (DPPG2-TSL-DOX). It has a different mode of action than conventional liposomes. Thermosome’s technology enables intravascular drug release initiated by a mild heat trigger using clinically established hyperthermia devices. This results in up to 15-fold higher local drug concentrations in the tumor and aims to improve clinical treatment efficacy by creating a local boost at the desired site of action. These high local concentrations, which also reach less well perfused areas, are intended to overcome drug resistance. This effect cannot be achieved by administration of conventional doxorubicin due to systemic toxicity. Thermosome intends to further enhance treatment efficacy through an additive immune response induced by regional hyperthermia. THE001 has potential for further development in other anthracycline-sensitive solid tumors, such as breast, bladder, and ovarian cancer. THE001 has been granted Orphan Drug Designation for STS in Europe and the United States. About the Phase I Study The Phase I, open-label, interventional dose-escalation trial enrolling patients with (including DOX-) pre-treated locally advanced unresectable or metastatic STS (NCT05858710) is being conducted at two German clinical sites testing THE001 at various different dose levels in initially up to 6 cycles every 3 weeks with option to extend to up to 12 cycles in participants with at least disease control. Both completed dose level (20 mg/m² and 40 mg/m²) were well tolerated and declared safe by the independent data safety monitoring board (DSMB). Primary endpoints of the study are the safety and tolerability of THE001 and the determination of the maximum tolerated dose. A secondary objective is the evaluation of anti-tumor activity. Initial clinical data were presented at the CTOS 2024 Annual Meeting (link). About Soft Tissue Sarcomas (STS) STS is an atypical tumor with a patient population that includes many young patients. Locally advanced STS (LA-STS) are large invasive tumors that are difficult or impossible to resect. Neoadjuvant therapy is used to shrink these tumors preoperatively to allow tumor surgery with curative intent. Free doxorubicin in combination with ifosfamide or dacarbazine has been the gold standard for neoadjuvant therapy of all chemo-sensitive LA-STS for several decades. Guidelines also recommend combining DOX-based therapy with regional hyperthermia. However, with response rates of less than 30%, there is a significant unmet need for improved treatment options. Soft tissue sarcomas occur in more than 50 different subtypes that do not share a common driver mutation, making biologic targeting more difficult than physically controlled targeting with the most active agent. Company ContactThermosome GmbHAm Klopferspitz 1982152 Planegg/Martinsried (Germany)Phone: +49 89 7167760 31media@thermosome.com Media InquiriesakampionDr. Ludger Wess / Ines-Regina Buth, Managing Partnersinfo@akampion.comPhone: +49 40 88 16 59 64 / +49 30 23 63 27 68
Lithuania Industrial Output Growth Slows to 11-Month Low - ForexTV
In May 2025, Lithuania's industrial production saw a year-on-year rise of 1.9%, a deceleration from the previously revised 2.5% increase recorded in April. This represents the eleventh consecutive month of growth in industrial activity, albeit the slowest within this growth sequence. The downturn was primarily due to a further decline in output for the mining and quarrying sector, which fell by 7.2% compared to a 5.4% decrease in April. Manufacturing production growth also slowed, recording a modest 1.2% increase compared to 2.3% in the previous month. Conversely, output for electricity, gas, steam, and air-conditioning supply reached a near three-year high, with an impressive surge of 22.6% compared to 8.1% in April. Meanwhile, the rate of decline in the water supply, sewerage, waste management, and remediation services sector eased slightly, registering a decrease of 1.9% compared to 2.1% previously. On a seasonally adjusted monthly basis, industrial activity rebounded with a 1.7% increase in May, recovering from an upwardly revised 3.1% decline in the prior period.The material has been provided by InstaForex Company - www.instaforex.com
LEADING EDGE MATERIALS' INVESTOR UPDATE AND SIGNIFICANT ACTIVITIES - ForexTV
LEADING EDGE MATERIALS’ INVESTOR UPDATE ON SIGNIFICANT ACTIVITIES Vancouver, June 22, 2025 – Leading Edge Materials Corp. (“Leading Edge Materials” or the “Company”) (TSXV: LEM) (Nasdaq First North: LEMSE) (OTCQB: LEMIF) provides an investor update on significant activities. Overview - Becoming a European CRM producer Concerns about critical raw materials - security of supply, supply chain resilience and defence requirements - have been recurring themes at conferences attended by the Company in recent months, with Heavy Rare Earth Elements (“HREEs”) and natural graphite frequently mentioned; geopolitical uncertainty is the new norm and it is driving partnership, collaboration and greater levels of support for mining. On June 17, 2025, the G7 Critical Minerals Action Plan was announced focused on ‘diversifying the responsible production and supply of critical minerals, encouraging investments in critical mineral projects and local value creation, and promoting innovation’ in the G7, and with partners beyond, working together and ‘to swiftly protect our economic and national security’'. At the EIT Raw Materials Summit in March, graphite and defence were frequent mentions on the first day, with widespread calls for more action, now the Critical Raw Materials Act is in force, and the need for more money. Against this backdrop, LEM’s Critical Raw Materials (“CRMs”) portfolio is very well positioned and the Company is working on becoming a European CRM producer. Norra Kärr is a globally significant source of HREEs with the economic advantage of valuable industrial minerals, specifically nepheline syenite; a production start within 3–4 years is in reach. In parallel, we are evaluating the restart of production from the fully built and permitted Woxna Graphite mine. On exploration, and possibly future production, we have strengthened our position in Romania, with Leading Edge Materials Romania (“LEMR”) being granted ownership and operational permits for the Avram Iancu mine by CNCAN (National Commission for Control of Nuclear Activities) under the supervision of IAEA (International Atomic Energy Agency) and European Atomic Energy Community (EURATOM). This is significant recognition of the funds invested and commitment made by the Company in country and gives us real ‘owner-operator’ autonomy over a deposit described as ‘one of the most important deposits [historically] in operation in Bihor (IAEA report, November 1997) and noted for uranium, copper, lead, nickel and zinc mineralization (IMWA Symposium 2007: Water in Mining Environments, May 2007). Norra Kärr – Application progresses On 8 April, the CEO was invited to Solvay’s inauguration of a new production line for rare earth permanent magnets (“REPM”) in France. Solvay is partnering with emerging mining and recycling players to accelerate the establishment of a robust, reliable, and sustainable supply chain, crucial for Europe’s competitiveness and industrial and technological sovereignty. The essential creation of a European rare earth supply chain was again the theme of Solvay’s presentation at The Rare Earth Industry Association (“REIA”) Conference in Montreal last week. In recent months, the Company’s application for a new Exploitation Concession (“Bearbetningskoncession”), 25-year mining lease has been out for consultation. The County Administrative Boards (CABs) of Jönköping and Östergötland have now communicated that they, at this time, cannot approve the Environmental Impact Assessment (“EIA”) submitted by the Company’s Swedish subsidiary GREENNA Mineral AB. The CABs state that additional data and analysis are needed. The decision and statement from the CABs tell us that we have some additional work to do describing the impact of the project, with an emphasis on water, cultural values and impact on other forms of land use. Obviously, these are crucial topics that must be addressed properly in our application. It should be noted that while the CABs reject our application as it currently stands, they also offer us the opportunity to supplement it. The Company’s Swedish environmental permitting team is already reviewing the comments from the CABs in detail, and we believe that we will be able to respond with supplementary information to our application to the satisfaction of the CABs and other stakeholders. Developing Norra Kärr is of the utmost importance not only for Sweden, but for Europe. Geopolitical tensions and unstable global trade flows mean that it is more important than ever to produce HREEs in Sweden. That will enable us to extract metals that are essential to both achieving a complete energy transition and secure our defences. Europe relies heavily on China for its imports of HREEs. China dominates all stages of the rare earth elements supply chain from mining to permanent magnet manufacturing. The speed at which China can build new production is awe inspiring, and, with an established industrial base decades in the making, it has the ability to innovate beyond anything Europe can dream. Europe is compelled to change its ways, think and act radically differently to have a secure future. Highlighting Sweden’s role in CRMs, Sweden’s Energy, Business and Industry Minister Ebba Busch recently stated that “Sweden has unique opportunities to be and remain a strong player in global mineral politics. We have the most sustainable mining industry in the world – ethically sustainable, environmentally sustainable, and with good working conditions.” The Company is developing and will manage Norra Kärr with social acceptance and transparency towards the local community as its primary considerations. The new application for mining license represents a reduction of 65 percent in land area compared to the old application which was initially approved in 2013. Chemical processing of the HREE-rich eudialyte concentrate will take place at an existing industrial location, and not on site. With the elimination of chemical processing, the Company has largely addressed stakeholder concerns about pollution risk to Lake Vättern. The changes to the application are in response to the public’s concerns to the old application. This is what responsible mining companies do, they listen. Proposed activities at site are now similar to those of a quarrying operation; similar to what already exists around Lake Vättern. Our target is to make products from 100% of what we extract, HREE-rich eudialyte concentrate and industrial mineral nepheline syenite being the two most critically important. Looking ahead, a Swedish mining license (sw. Bearbetningskoncession) is decided by the Chief Mining Inspector. If the Chief Mining Inspector and CABs disagree about an application, the Government can then make the decision. Our objective is to provide supplementary information and explanation on the sufficiency of our enhanced application to the full satisfaction of the CABs, so that the development of Norra Kärr can progress unimpeded. Alongside the mining lease process, Pre-feasibility (“PFS”) workstreams are underway. Testwork has now been completed on nepheline syenite and aegirine to determine their mineralogy, chemical composition, and leachate chemistry. The promising results are being used to determine possible market segments and specifications that can be achieved, potential demand and pricing, to be included in an updated PFS economic model for Norra Kärr. The Company envisages the PFS will be completed in Q1 2026. Woxna Graphite Mine – Potential Restart The Company is collaborating with an engineering consultant on updating the in-house production restart study, originally completed in 2022. We have initiated crushing testwork on Woxna ore to explore improved liberation and preservation of graphite flakes. Additionally, metallurgical testwork is planned to evaluate potential upgrades to the processing plant, aimed at optimizing performance. Our objective is to produce a high-quality, high-grade flake graphite concentrate. We continue to receive inbound enquiries and remain optimistic about Woxna’s future prospects. This ongoing workstream will support the development of a new business plan, which could facilitate future project financing discussions and potentially unlock access to Swedish or EU public funding. Bihor Sud – Major Milestone Exploration activities at the Bihor Sud project have continued steadily, bolstered by the addition of four new geologists who joined the team in January. Recent work has included underground mapping, diamond drilling, geophysical surveys, core logging, and sampling. To accelerate progress, the Company plans to change drilling contractors within the next one to two months. The Company remains focused on defining a large-scale, mineable mineral resource at Bihor Sud, particularly within gallery G2, where exploration is targeting promising zinc-lead-copper-silver mineralization. Results to date have been encouraging and highlight the project's strong potential for a significant polymetallic discovery. A major milestone was the granting of ownership and operational permits for the Avram Iancu mine. Historical mining and exploration at this site have left behind hundreds of kilometres of galleries and underground workings. In addition to ongoing work at G2, the Romanian team has initiated preliminary investigations at Avram Iancu. They successfully located the entrance to a 3-kilometre tunnel observed to be in good condition. Based on historical reports, this tunnel connects with up to 15 kilometres of workings and zones containing massive sulphides in carbonate-replacement deposits with primary copper-bearing minerals—including chalcocite and bornite. On behalf of the Board of Directors,Leading Edge Materials Corp. Kurt Budge, CEO For further information, please contact the Company at:info@leadingedgematerials.comwww.leadingedgematerials.com About Leading Edge Materials Leading Edge Materials is a Canadian public company focused on developing a portfolio of critical raw material projects located in the European Union. Critical raw materials are determined as such by the European Union based on their economic importance and supply risk. They are directly linked to high growth technologies such as lithium-ion batteries and permanent magnets for electric motors, wind turbines and defense applications. The portfolio of projects includes the 100% owned Woxna Graphite mine (Sweden), 100% owned Norra Kärr Heavy Rare Earth Elements project (Sweden), and the 51% owned Bihor Sud Nickel Cobalt exploration alliance (Romania). Additional Information The information was submitted for publication through the agency of the contact person set out above, on June 22, 2025, at 23:30 Vancouver time. Leading Edge Materials is listed on the TSXV under the symbol “LEM”, OTCQB under the symbol “LEMIF” and Nasdaq First North Stockholm under the symbol “LEMSE”. Svensk Kapitalmarknadsgranskning (“SKMG”) is the Company’s Certified Adviser for the Nasdaq First North Growth Market (Stockholm) and may be contacted via email ca@skmg.se or by phone +46 (0)8 913 008. Reader Advisory This news release may contain statements which constitute “forward-looking information”, including statements regarding the plans, intentions, beliefs and current expectations of the Company, its directors, or its officers with respect to the future business activities of the Company. The words “may”, “would”, “could”, “will”, “intend”, “plan”, “anticipate”, “believe”, “estimate”, “expect” and similar expressions, as they relate to the Company, or its management, are intended to identify such forward-looking statements. Investors are cautioned that any such forward-looking statements are not guarantees of future business activities and involve risks and uncertainties, and that the Company’s future business activities may differ materially from those in the forward-looking statements as a result of various factors, including, but not limited to, fluctuations in market prices, changes in the Company’s intended use of proceeds from the Private Placement, successes of the operations of the Company, continued availability of capital and financing and general economic, market or business conditions. There can be no assurances that such information will prove accurate and, therefore, readers are advised to rely on their own evaluation of such uncertainties. The Company does not assume any obligation to update any forward-looking information except as required under the applicable securities laws. Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accept responsibility for the adequacy or accuracy of this news release. Attachment 20250621 LEM - Update on Significant Activities FINAL
Enterome presents positive Phase 2 interim results in relapsed/refractory indolent non-Hodgkin lymphoma after EO2463 OncoMimics™ immunotherapy treatment at ICML - ForexTV
60% (12/20) complete response rate after treatment with EO2463 in combination with lenalidomide and rituximab (R2) EO2463 plus R2 was well tolerated in patients with follicular and marginal zone lymphomaEO2463 plus R2 combination treatment resulted in higher-than-expected rates of complete remission so far in this study compared to historical data for R2 alone Paris, France – 23 June, 2025 Enterome SA, a clinical-stage company developing first-in-class OncoMimics™ immunotherapies to treat cancer, presented positive interim results for its OncoMimics™ immunotherapy EO2463 from Cohorts 1 and 4 of the ongoing open label Phase 1/2 SIDNEY trial in patients with indolent non-Hodgkin lymphoma (iNHL), at the International Conference on Malignant Lymphoma (ICML) in Lugano. Interim data including 24 patients with follicular and marginal zone lymphoma (relapsed/refractory iNHL) showed that treatment with EO2463 in combination with lenalidomide and rituximab (R2) was well tolerated and demonstrated encouraging signs of efficacy that appear better than historical data in similar patients treated with R2. Importantly, EO2463 showed direct anti-lymphoma activity, including partial responses to the OncoMimics™ monotherapy, during the first six weeks of the study, a short time period during which just the first three doses of EO2463 were administered, before the protocol called for initiation of treatment with lenalidomide (followed subsequently by adding rituximab). Moreover, once lenalidomide and rituximab were added, the effect of EO2463 appeared to support a deepening of responses, resulting in a complete response rate of 60%, higher than would have been expected with R2 alone, based on historical data1. Pierre Belichard, CEO of Enterome said, “The EO2463 interim results are very encouraging, demonstrating exceptional tolerability for an active immunotherapy, and showing a clear signal that the combination with R2 can provide more robust responses in this patient population over R2 alone. This is consistent with the strong response rate we observed with EO2463 monotherapy in patients with low tumor burden disease, the so-called ‘watch-and-wait’ population, included in Cohort 2 of SIDNEY. While we plan to focus our near-term efforts on initiating a registrational Phase 3 trial of EO2463 for the watch-and-wait population, this evidence of a complementary effect in combination with R2 in relapsed/refractory iNHL is very exciting and offers new hope for this patient group, most of whom still see insufficient efficacy with available therapeutics.” EO2463 is designed to expand pre-existing memory CD8+ T cells recognizing non-self-protein sequences from gut bacteria, which mimic several purposefully selected B cell antigens. The interim SIDNEY data from Cohorts 1 and 4 presented at ICML show fast, robust, and durable expansion of the specific CD8+ T cells that were active against EO2463 mimic peptides and the targeted B cell epitopes. Most important, the magnitude of the EO2463-driven expansion of specific CD8+ T cells correlated with the probability of complete remission upon treatment with EO2463 combined with R2 in the SIDNEY study. EO2463 in combination with lenalidomide and rituximab (R2 ) is well tolerated in patients with follicular and marginal zone lymphoma. Jan Fagerberg, Chief Medical Officer of Enterome, said, “These early efficacy results suggest EO2463 offers additional benefit when used together with the R2 regimen in patients with relapsed/refractory iNHL. We previously reported data from Cohort 2 of SIDNEY, at ASH in December 2024, showing that EO2463 OncoMimics™ monotherapy generated a 46% objective response rate in patients who are usually proposed ‘watchful waiting’ and no active anti-lymphoma therapy – and also had an excellent tolerability profile. In short, taken together, these SIDNEY data indicate that this well tolerated novel active immunotherapy may well have broad potential across hematological malignancies.” EO2463 is an innovative, off-the-shelf OncoMimics™ active immunotherapy that combines four synthetic peptides. These non-self, microbial-derived peptides correspond to CD8 HLA-A2 epitopes that exhibit molecular mimicry with the B lymphocyte-specific lineage markers CD20, CD22, CD37, and CD268 (BAFF receptor). It also includes the helper peptide (CD4+ epitope) universal cancer peptide 2 (UCP2). The unique ability of EO2463 active immunotherapy to selectively target multiple B cell markers enables the destruction of malignant B lymphocytes. By ensuring broad target coverage across malignant B cells, this novel approach aims to simultaneously improve safety and maximize efficacy, reducing the tumor cells’ capacity to develop immune-resistance mechanisms such as antigen escape. SIDNEY is an ongoing open label Phase 1/2 study that aims to assess safety, tolerability, immunogenicity, and preliminary efficacy of EO2463 monotherapy and combination therapy with lenalidomide/rituximab in up to 55 patients with follicular lymphoma and marginal zone lymphoma including four cohorts of three patient populations: Cohort 2: patients with newly diagnosed, previously untreated low tumor burden disease, not in need of standard of care therapy, i.e., the “watch-and-wait” setting; treatment = EO2463 monotherapyCohort 3: patients with newly diagnosed, previously untreated low tumor burden disease, in need of therapy; treatment = EO2463 in combination with rituximab Cohorts 1 and 4: patients with relapsed/refractory disease and at least one prior treatment; treatment = EO2463 in combination with lenalidomide and rituximab (R2) OncoMimics™ are synthetically produced peptides designed in silico using AI and machine learning to mine Enterome’s extensive proprietary database of microbial bacteria. Unlike cancer antigens, OncoMimics™ bypass a gating process, known as thymic deletion, that prevents the immune system from mounting an attack against the “self” proteins (e.g. antigen) on tumor and blood cancer cells. Furthermore, that they trigger a more targeted, rapid and robust immune response than would otherwise be possible, because very early in human development the immune system learns to protect the body from microbiome bacteria. This means that OncoMimics™ call up memory CD8+ T cells that selectively target the cancer cells that carry the mimicked antigen(s). This therapeutic strategy takes inspiration from and is de-risked by emulating the gut microbiome’s causal role in certain autoimmune diseases. OncoMimics™ are easy to manufacture, store, distribute and administer as an “off-the-shelf” subcutaneous injection. In clinical testing to date they have been shown to be extremely well tolerated, especially compared to other potent immunotherapies. Enterome SA (www.enterome.com) is a privately held clinical-stage biopharmaceutical company developing breakthrough OncoMimics™ immunotherapeutics for cancer. The three most advanced product candidates have shown positive early data in Phase 2 clinical development, supporting novel OncoMimics™ modality. The company’s pioneering approach to drug discovery is based on the unique and powerful bacterial Mimicry drug discovery platform, which allows it to discover OncoMimics™ with high similarity to tumor associated antigen (TAA) based on the big-data insights from millions of gut bacterial proteins, that live in humans. For more information, please contact: ENTEROMEPierre BelichardChief Executive Officer+33 (0)1 75 77 27 85communication@enterome.com INVESTOR & MEDIA RELATIONSCohesion BureauChris Maggos / Giovanni Ca’ Zorzi+41 (0)79 367 6254 / +33 (0)7 84 67 07 27enterome@cohesionbureau.com 1 https://doi.org/10.1200/JCO.22.00843 Attachment 20250623 Enterome PR#6 - Lugano data_final_EN
ITM and Debiopharm Announce First Patient Imaged in New Study Arm of Phase 1/2 Trial Evaluating ITM-94 as Diagnostic Agent for Clear Cell Renal Cell Carcinoma (ccRCC) - ForexTV
New study arm (Part D) is part of the broad clinical development plan of the ITM-91/ITM-94 theranostic program in patients with Carbonic Anhydrase IX (CAIX)-expressing tumors Part D builds on promising imaging data demonstrated in Part A of the study for ITM-94, a Gallium-68 (68Ga)-labeled PET imaging candidate, as a diagnostic agent for early-stage clear cell renal cell carcinoma (ccRCC)Together with ITM-91, a Lutetium-177 (177Lu)-labeled radiotherapeutic candidate, ITM-94 is a theranostic pair, which ITM licensed exclusively from Debiopharm for clinical and commercial development in September 2024 Garching / Munich, Germany, and Lausanne, Switzerland - June 23, 2025 – ITM Isotope Technologies Munich SE (ITM), a leading radiopharmaceutical biotech company and Debiopharm, a Swiss-based, global biopharmaceutical company aiming to establish tomorrow’s standard-of-care to cure cancer and infectious diseases, today announced that the first patient was imaged in a new study arm of a five-part, Phase 1/2 clinical trial (formerly GaLuCi™) (NCT05706129) evaluating the theranostic pair ITM-94/ITM-91 for identification and treatment of patients who have unresectable, locally advanced or metastatic solid tumors. As a new component of a broad clinical development plan for ITM-91/ITM-94, Part D of the trial will evaluate the effectiveness of ITM-94 in classifying indeterminate renal mass as either ccRCC or non-cancerous. ITM-91/ITM-94 is a first-in-class, peptide-based theranostic pair combining the radiotherapeutic compound ITM-91 (Debio 0228) ([177Lu]Lu-DPI-4452), with the diagnostic agent ITM-94 (Debio 0328) ([68Ga]Ga-DPI-4452) to target Carbonic Anhydrase IX (CAIX). CAIX is a cell surface protein that plays a key role in the tumor microenvironment, promoting tumor growth, survival, invasion and metastasis. In September 2024, ITM gained the exclusive worldwide license from Debiopharm for the development and commercial rights of ITM-91/ITM-94. The initiation of this study arm represents a significant advancement for ITM and Debiopharm following their licensing agreement. In the now initiated Part D of the trial, ITM-94 is being evaluated for its effectiveness to accurately classify an indeterminate renal mass as ccRCC or non-cancerous, when compared to CT/MRI imaging and histopathology. Secondary endpoints include sensitivity, specificity, and the positive and predictive value of ITM-94 PET/CT imaging compared to histopathology. This study arm is expected to enroll approximately 36 patients at around 15 clinical sites across the EU, US and Australia. “The early results from the Gallium-68 CAIX PET/CT diagnostic are remarkable to date. I believe ITM-94 has the potential to change the way urologists and oncologists diagnose and stage patients with clear cell renal cell carcinoma, improving accuracy and reducing the need for biopsies. I have not seen a tracer with a similar profile since the PSMA PET/CT was established,” added Prof. Michael Hofman, Director, Prostate Cancer Theranostics and Imaging Centre of Excellence (ProSTIC), Peter MacCallum Cancer Centre, Melbourne, Australia. “Clear cell renal cell carcinoma is the most common form of kidney cancer, with more than 90% of cases overexpressing the CAIX encoding gene. As survival rates are highly dependent on the stage of progression, rapid and precise diagnosis is essential to provide patients with the best possible treatment options and therapeutic outcomes. ITM-94 has already demonstrated potential exceptional imaging qualities, including high tumor-to-background ratios and detecting lesions not visible by CT scan with a potential favorable safety profile. We look forward to exploring the full potential of the theranostic pair ITM-91/ITM-94 across this trial to characterize and treat CAIX expressing cancer cells, advancing the efficacy of targeted radiopharmaceutical therapies,” said Dr. Celine Wilke, Chief Medical Officer of ITM. “With high-quality imaging and high tumor uptake, ITM-94 has already demonstrated potentially significant diagnostic capabilities in solid tumors. The data gathered in Part D of the trial will be instrumental to the further validation of this theranostic pair. We highly value our partnership with ITM, which will continue to advance the rapid progression of these novel radio-diagnostics and -therapeutics through the clinic,” said Angela Zubel, Chief Development Officer, Research & Development at Debiopharm. About the Phase 1/2 ITM-91/ITM-94 TrialThe five-part clinical trial (NCT05706129) is designed to assess the safety and tolerability, imaging characteristics, and efficacy of the theranostic pair ITM-91/ITM-94 in patients with unresectable, locally advanced or metastatic solid tumors. In Part A of the trial, ITM-94 demonstrated exceptional tumor imaging characteristics, with a high tumor-to-background ratio and a favorable tolerability profile in patients with confirmed ccRCC, with results published in the Journal of Nuclear Medicine. Part B, which is ongoing, is assessing escalating doses of the therapeutic agent, ITM-91, in patients whose tumors show high uptake of the imaging tracer. Based on the recommended dose from Part B, Part C of the trial will assess the safety and preliminary efficacy of ITM-91 in patients with ccRCC, pancreatic ductal adenocarcinoma, colorectal cancer, urothelial carcinoma and potentially other tumor types. In addition to the newly initiated Part D, Part E will assess ITM-94 uptake in other tumors. ITM will assume full sponsorship of the program from Debiopharm once the transfer is completed. About ITM-91/ITM-94 (Debio 0228/ 0328) ITM-91/ITM-94 is an investigational theranostic pair originally discovered by 3B Pharmaceuticals GmbH and now exclusively licensed to ITM. ITM-94 ([68Ga]Ga-DPI-4452) is a PET imaging agent that may be used independently and is designed to identify patients whose cancers overexpress CAIX. Once identified, these patients may be treated with the lutetium-labelled radioligand, ITM-91 ([177Lu]Lu-DPI-4452), which delivers targeted radiation to the tumor with the aim to destroy it from the inside.About ITM Isotope Technologies Munich SEITM, a leading radiopharmaceutical biotech company, is dedicated to providing a new generation of radiopharmaceutical therapeutics and diagnostics for hard-to-treat tumors. We aim to meet the needs of cancer patients, clinicians and our partners through excellence in development, production and global supply. With improved patient benefit as the driving principle for all we do, ITM advances a broad precision oncology pipeline, including multiple Phase 3 studies, combining the company’s high-quality radioisotopes with a range of targeting molecules. By leveraging our two decades of pioneering radiopharma expertise, central industry position and established global network, ITM strives to provide patients with more effective targeted treatment to improve clinical outcome and quality of life. www.itm-radiopharma.comDebiopharm’s commitment to patientsDebiopharm aims to develop innovative therapies that target high unmet medical needs in oncology and bacterial infections. Bridging the gap between disruptive discovery products and real-world patient reach, we identify high-potential compounds and technologies for in-licensing, clinically demonstrate their safety and efficacy, and then select large pharmaceutical commercialization partners to maximize patient access globally. For more information, please visit www.debiopharm.com. We are on X. Follow us @DebiopharmNews at http://twitter.com/DebiopharmNews or on LinkedIn. ITM ContactCorporate CommunicationsKathleen Noonan/Julia WestermeirPhone: +49 89 329 8986 1500Email: communications@itm-radiopharma.com Investor RelationsBen OrzelekPhone: +49 89 329 8986 1009Email: investors@itm-radiopharma.com Debiopharm ContactDawn Bonine - Head of Communicationsdawn.bonine@debiopharm.com Tel: +41 (0)21 321 01 11 Attachment 20250623_ITM and Debiopharm Announce First Patient Imaged in New Study Arm Evaluating ITM-94 as Diagnostic Agent for Clear Cell Renal Cell Carcinoma
Lebanon Inflation Rate Rises to 3-Month High - ForexTV
The inflation rate in Lebanon saw an uptick to 14.4% in May 2025, compared to 13.0% in the month before. This represents the highest rate since February, largely due to an accelerated increase in prices for food and non-alcoholic beverages, which climbed to 21.4% from April's 20.9%. Housing and utilities experienced notable price growth, rising to 18.0% from 15.8%, while the recreation and culture sector saw its rates increase to 6.1% from 4.8%. Costs for furnishings, household equipment, and routine maintenance reversed their previous decline, jumping by 3.2% after an 8.4% fall in the previous period. However, there was a slowdown in inflation for clothing and footwear, which eased to 10.3% from 11.0%, and for restaurants and hotels, which decreased to 13.5% from 14.9%. On a month-to-month basis, consumer prices rose by 1.3%, following a 0.7% increase in April.The material has been provided by InstaForex Company - www.instaforex.com
SenturoPay Launches Comprehensive Crypto Payment Card for Everyday Users - ForexTV
Platform enables seamless sending, swapping, and spending of digital assets through a secure, easy-to-use interface designed for everyday financial needs.Hong Kong, June 23, 2025 (GLOBE NEWSWIRE) -- SenturoPay, a fast-growing digital finance platform, today announced the official launch of its all-in-one crypto payment card, developed to help users manage and utilize their digital assets in everyday life. With features designed to send, swap, and spend crypto, the platform delivers a real-world solution for individuals looking to simplify how they interact with their crypto holdings. “This isn’t a tech showcase—it’s a lifestyle tool,designed with our users' convenience in mind." said a Co-Founder at SenturoPay.“We’ve built a crypto experience that mirrors what users already expect from modern finance—clear, responsive, and practical.” Making Crypto Work for the Real World While crypto adoption continues to expand, many platforms remain focused on trading or storage, leaving users with limited ways to access their assets for real-world needs. SenturoPay fills that gap by offering a comprehensive crypto app and payments system tailored for ease of use and day-to-day functionality. With just a few taps, users can: Send crypto instantly to other users or external walletsSwap crypto between supported tokens directly in the appSpend crypto using virtual cards linked to their balances Everything is managed through a centralized, secure dashboard, giving users full control and visibility over their digital finances. Key Platform Features Send Crypto InstantlySeamlessly transfer digital assets to peers, with zero unnecessary steps or manual delays.Swap Crypto On-DemandConvert between supported tokens through a built-in swap function—no need for third-party exchanges.Spend Crypto SecurelyCreate virtual crypto cards that can be used online, funded directly from the user's appin real time.Unified App InterfaceA clean and intuitive dashboard helps users track balances, view transaction history, and manage activity without confusion. Designed for Mass Adoption SenturoPay is intentionally built for a wide range of users—from crypto newcomers to digital natives. Its emphasis on clarity, simplicity, and utility sets it apart from platforms that require a steep learning curve or technical fluency. “We’ve designed SenturoPay so that anyone—regardless of their crypto background—can access, manage, and use their assets confidently,”added the spokesperson.“It’s about giving people tools that make digital money practical, not just possible.” About SenturoPay SenturoPay is a digital finance platform focused on turning crypto into a usable, everyday financial tool. With a strong emphasis on simplicity, security, and practical use cases, the platform offers users a streamlined way to send crypto, swap tokens, and spend digital assets through one integrated experience. To learn more, visit SenturoPay’s official website. CONTACT: Media Team support@senturopay.com
Lithuania Sees a Rebound in Industrial Production, Rising to 1.7% in May - ForexTV
In a significant turnaround, Lithuania's industrial production surged by 1.7% in May 2025, as per the latest data updated on June 23, 2025. This marks a substantial improvement from the previous month, where April witnessed a dip of -3.00%. This month-over-month comparison highlights a noteworthy recovery in the Lithuanian industrial sector.The shift into positive territory is crucial for Lithuania as the nation strives to stabilize its industrial output amid challenging economic conditions. The rebound suggests potential optimism for the country's economic trajectory and reflects the resilience of its industrial base.The May figures bolster hopes for sustained growth as Lithuanian industries appear to adapt and respond to economic pressures. Analysts will keenly watch if this positive trend can be maintained in the coming months, providing a much-needed uplift to the broader economic landscape in the region.The material has been provided by InstaForex Company - www.instaforex.com
Silver Muted Amid Escalating Middle East Crisis - ForexTV
Silver prices remained around $36 per ounce on Monday, stabilizing after two consecutive days of decline. This occurred as markets reacted to a significant escalation in Middle East tensions. Over the weekend, the U.S. launched airstrikes on three Iranian nuclear sites, joining forces with Israel in its conflict with Iran, and sparking concerns over potential Iranian retaliation. The heightened geopolitical risk propelled demand for the U.S. dollar as a safe haven, which in turn exerted downward pressure on both silver and gold prices. Last week, silver prices surged to heights not seen in over 13 years, driven by safe-haven inflows—particularly as an alternative to gold—coupled with indications of robust industrial demand and tight supply conditions. However, the recent rally has faltered, with declines attributed to profit-taking and liquidity pressures as investors moved to cover losses in other asset classes.The material has been provided by InstaForex Company - www.instaforex.com
Danish Business Morale Improves - ForexTV
In June 2025, Denmark's manufacturing confidence indicator rose to 98.4, up from May's 96.3, which was the lowest point since December 2023. Despite this increase, the indicator remains below the historical norm of 100. This development represents the first rise in manufacturing confidence in four months. The improvement is largely attributed to enhanced employment expectations, which shifted to a positive outlook (5 as compared to -7 in May). Furthermore, there was a significant boost in household sentiment towards production, jumping to 20 from 14, indicating a more optimistic perspective.The material has been provided by InstaForex Company - www.instaforex.com
Antonio Filosa Announces New Stellantis Leadership Team on First Day as CEO - ForexTV
Antonio Filosa Announces New Stellantis Leadership Team on First Day as CEO AMSTERDAM, June 23, 2025 – Antonio Filosa today takes up the role as Chief Executive Officer of Stellantis N.V. and announces his new Stellantis Leadership Team, effective immediately, drawing on the deep bench of industry expertise from Stellantis’ teams around the world. “It is my great privilege to take the lead of Stellantis, a global company with deep regional roots,” said CEO Antonio Filosa. “We have unique strengths in our great people, our iconic brands and our millions of customers, whose loyalty to our Company, its fantastic products and its unique stories can only inspire us to new achievements.” The new appointments, which build on the organizational changes announced in February 2025, underline Stellantis’ breadth and depth of talent. The team structure emphasizes the choice of locating product decision-making close to the regions where Stellantis’ cumulative knowledge is second to none, harnessing the power and emotion of its brands to meet and exceed the needs and desires of its customers worldwide. Antonio Filosa added: “The team I’m announcing today draws on all that is best in Stellantis, leaders from within who bring a people-first mindset, a profound understanding of our brands, our products and our customers, best-in-class expertise and an entrepreneurial spirit that will be vital to our success. We all share an immense pride in our history and a constant dedication to building our future together, and in close collaboration with our dealers, suppliers, partners and communities. With the talent and passion of this team, we will harness our multiple strengths to make Stellantis one of the winners in this next era for our Company and our industry.” The Stellantis Leadership Team (SLT) announced today is as follows: Antonio Filosa, CEO, retains his role as head of North America and American Brands. Doug Ostermann, CFO, takes responsibility for mergers and acquisitions and joint ventures. Jean-Philippe Imparato continues in his role as head of Enlarged Europe & European Brands, which will now also include Maserati. Emanuele Cappellano joins the SLT in his role of head of South America and takes responsibility for Stellantis Pro One, the Company’s commercial vehicles business unit.Philippe de Rovira is appointed to lead Rest of World and retains responsibility for Stellantis Financial Services.Davide Mele joins the SLT to lead Product Planning.Ned Curic continues his leadership of Product Development & Technology.Sébastien Jacquet, who was appointed head of Quality earlier this month, joins the SLT. Monica Genovese is appointed head of Purchasing. Scott Thiele takes on a newly created role as head of Supply Chain and joins the SLT, bringing together activities previously located in Planning and Manufacturing. Arnaud Deboeuf continues to lead Manufacturing.Xavier Chéreau continues to lead Human Resources and Sustainability.Clara Ingen-Housz joins the SLT in her role as head of Corporate Affairs & Communications. In addition to the Stellantis Leadership Team, the following four executives will also report directly to the CEO: Ralph Gilles as head of Design. Olivier Francois as head of Marketing.Alison Jones now leads Parts & Services and Circular Economy. Giorgio Fossati as General Counsel. Richard Palmer will continue as a strategic advisor to the Company. Antonio Filosa concluded: “As we move into this next chapter of our Stellantis history, I would like to take this opportunity to express my sincere thanks to Maxime Picat and to Béatrice Foucher for their notable contributions to Stellantis during their many years of dedicated service. We all wish them the best in their future endeavors.” Biographies and photos are available at the following link: https://www.stellantis.com/en/company/governance/stellantis-leadership-team # # # About Stellantis Stellantis N.V. (NYSE: STLA / Euronext Milan: STLAM / Euronext Paris: STLAP) is a leading global automaker, dedicated to giving its customers the freedom to choose the way they move, embracing the latest technologies and creating value for all its stakeholders. Its unique portfolio of iconic and innovative brands includes Abarth, Alfa Romeo, Chrysler, Citroën, Dodge, DS Automobiles, FIAT, Jeep®, Lancia, Maserati, Opel, Peugeot, Ram, Vauxhall, Free2move and Leasys. For more information, visit www.stellantis.com @StellantisStellantisStellantisStellantisFor more information, contact:Fernão SILVEIRA +31 6 43 25 43 41 – fernao.silveira@stellantis.comNathalie ROUSSEL +33 6 87 77 41 82 – nathalie.roussel@stellantis.comcommunications@stellantis.comwww.stellantis.com Attachment ENG_06232025_AF Day 1 and Leadership Team_FINAL-FINAL